Detection of Epstein-Barr virus DNA in nasopharyngeal carcinomas and other head and neck tumours. by Tsui, Hon-wing. & Chinese University of Hong Kong Graduate School. Division of Clinical and Pathological Sciences.
DETECTION OF EPSTEIN-BARK VIRUS DNA IN
NASOPHARYNGEAL CARCINOMAS
AND
OTHER HEAD AND NECK TUMOURS
by
Hon-wing Tsui
Thesis submitted as partial fulfilment for
the degree of Master of Philosophy
Jolly, 1988
Division of Clinical and Pathological Sciences
Graduate School
The Chinese University of Hong Kong

THESIS COMMITTEE
Dr. Dolly P. Huang
Prof. Joseph C. K. Lee




I would like to express my deepest gratitude to my
chief supervisor, Dr. Dolly P. Huang, for her patient
guidance, valuable advice, suggestions, discussion and
constant encouragement during years of my study and on
the preparation of this thesis.
I also wish to express my gratitude for helpful
criticism and informative suggestions made by my thesis
committee: Prof. Joseph C. K. Lee, Dr. S. Y. Tsao, and
Prof. H. Wolf.
I am indebted to Dr. M. Arnold, Dr. L. J. McGuire,
Dr. H. K. Ng and Dr. K. Wong for providing me the
biopsies. I am also thankful for Prof. R. Swaminathan,
Mrs. Angela Jen, Mr. David S. Y. Lo, Mr. K. Y. Lo, Mr.
Gary Yiu, and Ms. M. L. Lee to give me their technical
assistance, valuable discussions and encouragement.
Finally, I would like to express my whole-hearted
gratitude to all the staff in the Pathology Department,













D. Possible etiology 15
a) History of priro ear, nose and
throat diseases
b) Occupation










C. Early lymphocytic production
D. Lymphoblastoid cell line
E. Undifferentiated epithelial cell
line
F. Well differentiated epithelial cell
line
IV. Epstein-Barr virus 30
A. Morphology
B. Genome structure
C. Epstein-Barr virus-associated antigens
a) Epstein-Barr virus nuclear
antigens




e) Viral capsid antigens
V. Epstein-Barr virus and nasopharyngeal
carcinoma 45
A. Relationship between WHO 2 & 3 NPC
a) Serological markers for Epstein-
Barr virus association
b) Electron microscopic studies
c) Detection of Epstein-Barr virus
genome
B. Relationship between WHO 1 NPC
a) Serological profile
b) Detection of Epstein-Barr virus
genome








of organ transplant recipients
c) B-cell lymphomas in disease-
related immunodeficiency
d) B-cell lymphoma at immunological
previlleged sites
e) other carcinomas of the head and
neck region
VII. AND hybridization method 70
Reassociation kineticsA.
B. Filter hybridization
a) Dot blot hybridization
b) Southern blot hybridization
C. In situ hybridization
MATERIALS AND METHODS








A. NPC/HK1 and Raji
a) Cell preparation





f) Dialysis and concentration
measurement
B. Raji and cord blood lymphocytes
C. Tissue biopsies
IV. Preparation of radioactive probe 102
A. Nick-translation
B. Trichloracetic acid precipitation
V. Dot blot filter preparation
105
A. Set up of sample appliation apparatus
B. Sample application
VI. Southern blot filter preparation
108
A. Restriction enzyme digestion
B. Agarous gel electrophoresis
C. Southern transfer
VII. AND hybridization 112




B. southern blot filter
RESULTS
I. DNA extraction 115
II. Nick-translation 115
III. Agarose gel electrophoresis 118
IV. Optimal stringency washing condition 118
V. Sensitivity of DNA hybridization 118
VI. Dot blot hybridization result
A. NPC/HK1 cell line and normal
nsopharyngeal biopsies
121
B. Salivar gland tumors and carcinoma
of tongue 121
C. Different kinds of thymus tissue 122
VII. Southern blot hybridization result
A. NPC/HK1, WHO 3 NPC and normal
nasopharyngeal tissues
126
B. Different head and neck tissues 126
C. Different thymus tissues 127
DISCUSSIONS
I. Methods 131
II. Lack of Epstein-Barr virus DNA in
NPC/HK1 133
III. Lack of Epstein-Barr virus AND in normal
hasopharyngeal bioopsies 136
IV. Epstein-Barr virus DNA in submandibulan
lymph node with lymphoepithelioma-like
metastasis 138
V. Lack of Epstein-Earr virus in carcinoma
of the base of tongue 139
VI. Epstein-Barr virus DNA in undifferen-
tiated carcinoma of the parotid gland 140






1. Southern blot hybridization and dot blot hybridi¬
zation were developed by me in our laboratory.
Using 32P-labeled Epstein-Barr virus BamHI-W repeat
cloned into the pBR322 plasmid as probe, these
methods could detect 100 pg pure BamHI-W fragment
and those repeats in O.Olug of Raji DNA.
2. Using these techniques, the well differentiated
nasopharyngeal carcinoma cell line, the NPCHK1, and
the normal nasopharyngeal tissues were found to
contain no Epstein-Barr virus BamHI-W fragment.
Whether these are due to the non-existence of the
viral genome, comparatively low sensitivity of the
DNA-DNA hybri-dization method, or the line contains
fragments other than BamHI-w, was discussed.
3. The Epstein-Barr virus BamHI-W fragment was detected
in a Chinese patient with undifferentiated carcinoma
of the parotid gland. This is the first case
reported in Hong Kong that both serological profile
as well as DNA analysis are consistently supporting
an association with Epstein-Barr virus. On the
other hand, no Epstein-Barr virus DNA was found in a
patient with adenocarcinoma in the parotid gland.
INTRODUCTION
The Epstein-Barr virus (EBV), a member of the
herpes group virus, is initially isolated from a
Burkitt's lymphoma tumor. It is an ubiquitous B-
lymphotropic virus responsible for infectious mononu¬
cleosis and is one possible etiological agent of
African Burkitt's lymphoma and undifferentiated type
nasopharyngeal carcinoma. In fact, taking Burkitt's
lymphoma as an example, the Epstein-Barr virus has
satisfied all the criteria proposed by Henle [1] for an
oncogenic virus:
a. viral particles are present in the tumor cells;
b. patients have elevated antibodies titres to EBV-
specific antigens;
c. virus itself can immortalized human B-lymphocytes
in vitro; and
d. is capable of inducing tumors in the sub-human
primates.
During the past two decades, lots of works had
been done in western countries to elucidate the
oncogenic role of EBV. However, except for
undifferentiated type NPC, most of the tumor patients
lack elevated EBV-specific antibodies titres. Thus in
order to confirm whether there is an association
between the tumors and virus, people try to detect the
viral DNA in the tissues. This is done by using DNA
the hybridization techniques.
In Hong Kong, like other areas in Southern China,
the NPC is a major killer among cancer patients.
Although intensive studies have been done in here as
well as in other countries on undifferentiated type
NPC, only very few works involved the well differen¬
tiated type. In order to get more information about
this rare tumor type, I tried to detect EBV DNA in a
well differentiated NPC cell line. In the same way,
since no EBV-DNA hybridization studies have been done
on other tumors in Hong Kong, I also tried to detect
the EBV DNA in various head and neck tumor biopsies.
LITERATURES REVIEW
I. Anatomy of the nasopharynx
A. Anatomical location
The nasopharynx consists of the uppermost
(nasal) portion of the pharynx. The terms post¬
nasal space [2] and epipharynx [3] are its
alternative name. It is roughly cuboidal in shape
and consists of six walls.
a) The anterior wall: it is formed by the
posterior nares, the choanae, through which
the nasopharynx communicates with the nasal
fossae.
b) The inferior wall: it is formed by the upper
surface of the soft palate.
c) The roof and the posterior wall: they form a
continuous sloping surface bounded by the
basilar part of the occipital bone, part of
the basisphenoid and the first two cervical
vertebrae.
d) The two lateral walls: they are symmetric and
represent the largest surface area of the
nasopharynx. They contain the pharyngeal
orifice of the eustachian tubes which are
surrounded by the torus tubarius, the salience
of cartilage above and behind the opening.
The fossa of Rosenmuller, or the pharyngeal
recess, is a depression of the posterior
lateral walls just behind the torus tubarius.
All the cancers take place in the anatomical
site defined by the above limits are coded as
malignant neoplasms of the nasopharynx (ICD 147)
[4]. Since the nasopharynx is close to many
important pathways to the cranium, tumors arise in
this area may gain access to the cranial cavity.
Infiltration of the nasopharyngeal carcinoma cells
through foramen lacerum is a good example [5].
B. Histology
Microscopically, the nasopharynx has two
prominent tissues: the lymphoid tissue that forms
the upper portion of the Waldeyer's ring, and the
epithelium which provides a protective covering
for the lymphoid tissue.
The mucosa of the nasopharynx consists of
numerous folds and crypts. It contains three
types of epithelium: stratified sguamous
epithelium, pseudo-stratified ciliated columnar
epithelium and transitional epithelium [6]. Based
on the necrosy studies in 100 persons between the
ages of 10 and 80 years belonging to four racial
groups in Singapore, 60% of the whole epithelial
surface is covered by stratified sguamous epithe¬
lium irrespective of age, sex, or race. In both
the roof and the lateral walls, alternating
patches of squamous and ciliated epithelium
separated by islets of intermediate epithelium can
be found. The squamous epithelium is largely non-
keratinizing but areas of keratinization and
acanthosis are present in individuals over the age
of 50 years.
The pseudostratified ciliated columnar
epithelium is similar to that of the upper
respiratory tract. Numerous goblet cells are
lying between them. According to Yeh,s observa¬
tion [7], only those still-born and new born
infants have the nasopharynx solely covered by
ciliated epithelium. With age, they undergo
squamous metaplasia [7,8,9]. Ali [6] considered
that this transformation took place during the
first decade of life. In adult, about 40% of the
anterior wall and only 15- 20% of the posterior
wall are lined by ciliated epithelium.
The transitional or intermediate epithelium
is similar to those lining the urinary system.
Under electron microscope, it differs from that in
the urinary system by lacking fuciform vesicles in
the apical cytoplasm [10]. Keratohyalin are
present in the superficial layer. It is histo-
chemically related to squamous epithelium.
Underlying the epithelium, numerous lymphoid
cells exist. This feature makes the nasopharyn-
geal mucosa distinct from the rest of the respira¬
tory tract. It is also called lymphoepithelium.
II. Nasopharyngeal carcinoma
A. Incidence
Nasopharyngeal cancer, just like other
cancer, consists of a variety of histological
types [11]. The five year survival rate following
the diagnosis is approximately 30% in almost all
populations [12,13,14,15,16,17], Among all these
cancer cases, the non-glandular epithelial-derived
nasopharyngeal carcinoma (NPC) comprises the vast
majority in endemic areas.
By definition, NPC is a malignant tumor of
the epithelium lining the surface and crypts of
the nasopharynx [11]. It predominantly occurs in
those living in the southeastern provinces of
China especially Kwangtung province (Guandong)
[18,19,20,21,22,23], or those born there but have
migrated to other parts of southeast Asia and
beyond [14,24,25,26,27,28,29]. Interestingly, a
dialect group prevalence can also be seen. For
example, The Cantonese has a significant higher
incidence than those from the Chiu Chau district
(known as Teochew in Singapore) [24,30,31,32,33].
In addition to southeastern China, NPC is also
prevalent in Eskimos [34,35,36,37], Filipinos
[38,39,40], Malays [41] and some groups near the
Mediterranean Sea [42,43,44,45].
In non-Chinese populations of the world,
nasopharyngeal carcinoma is rare, with age-
adjusted incidence rate less than 1 per 100,000
[45]. The worldwide sex ratio between male and
female is 2:1 to 3:1 [22,29,45,46,47,48,49,50],
This male predominance is similar to most other
head and neck tumors [51,52,53],
In Hong Kong, NPC is the main cause of cancer
death especially for male. The mortality for male
and female was 11.3 and 3.6 per 100,000
respectively in 1985 [54]. In 1978, the age
adjusted incidence rate was 36.5 and 15.5 [56]
(male versus female). Although the lung cancer
showed a three-folds increase in incidence over
the past 19 years, the incidence of NPC kept
unchanged. Nevertheless, a rightward shift in
starting point of the incidence peak [56,55] was
observed from 1974 to 1978 (from twenty years to
thirty years old).
Among all the NPC patients in Hong Kong,
boat people or Tanka who engaged in fishing as a
livelihood are about two-folds higher risk than
the rest of the population [14]. Since it is
unlikely that they are exposed more frequent to
certain carcinogenic inhalants than those in other
areas, this prevalence may due to salted fish
ingestion [14,57]. It will be discussed later.
B. Pathology
Grossly, NPC may arise in any parts of the
nasopharyngeal mucosa. It may develop into:
a) ulcerative form: small and necrotic lesions,
capable of progressively infiltrating the
neighboring tissues;
b) nodular form: with a grapelike, polypoid
appearance and may not show ulceration
anywhere on its surface;
c) exophytic form: hemispheric and sometimes
pedunculated or;
d) lesions with mixed features [58,59].
In view of the tumor location, the lateral
wall containing the fossa of Rosenmuller (or the
pharyngeal recess) is the commonest site, while
the posterior wall is slightly less so. Less
commonly a tumor is found on the roof and only
rarely on the floor [60]. For undifferentiated
NPC, numerous non-neoplastic lymphocytes exist
between nexus of large epithelial cells [15].
Cytologically, they belong to the T-lineage [61].
Using monoclonal antibodies, Herait and associates
[62] had proved that these infiltrating
lymphocytes were activated T-cells rather than
remnant cells present in the normal nasopharyngeal
mucosa. However, they were not seen in the
metastasis in non-lymphoid tissues such as the
liver [63,64]. Local infiltrates of the tumors
may involve the nasal fossae, paranasal sinuses,
orbital cavities, eustachian tubes, oropharynx,
buccal cavity, parotid gland, and cranial cavity.
Lymphatic spread may involve retropharyngeal nodes
as well as the upper and posteriorly placed
cervical nodes [65]. Clinically, most NPC
patients develop a cervical adenopathy without any
symptoms referable to a primary lesion in the
nasopharynx. The most common other symptoms are
tinnitus, epistaxis, hypoacousia, nasal
obstruction, ophthalmoplegia, and pain.
The histiogenesis of NPC is very controver¬
sial. It has been claimed to be arising from
transitional (intermediate) epithelium [66], pseu-
dostratified ciliated columnar epithelium [67],
and stratified squamous epithelium [64]. Based
on the observation of in-situ malignant change and
continuity of the tumor with surface epithelium,
Shanmugaratnum Muir [68] suggested that all
histological types of NPC may arise from any
epithelial types lining the surface and crypts of
the nasopharynx.
C. Classification
Several different classifications have been
suggested. They range from dividing the tumors
into two broad histologic types such as keratini¬
zing versus non-keratinizing groups [69], well
differentiated squamous cell carcinoma versus
anaplastic carcinoma [70], squamous cell carcinoma
versus undifferentiated carcinoma [71,72], to
those dividing NPC into a variety of subtypes
[7,8]. However, as recommended by international
symposia [73,74], pathologists should use the
system proposed by the World Health Organization
(WHO) [11] to promote comparability [75]. The
system proposed three histologic types:.
1. Keratinizing squamous cell carcinoma
NPC showing definite evidence of squamous
differentiation with the presence of
intercellular bridges under light microscope.
2. Nonkeratinizing carcinoma
The tumors showing evidence of differentia¬
tion, but in which squamous maturation is not
obvious; the tumor cells have well-defined
cell margins and show a stratified or
pavemented arrangement with a plexiform
pattern; some of these tumors exhibit clear
cell structure caused by the presence of
cytoplasmic glycogen.
3. Undifferentiated carcinoma
The tumor cells have oval or round vesicular
nuclei and prominent nucleoli. The cell
margins are indistinct and the tumor exhibits
a syncytial rather than pavemented appea¬
rance.
The term lymphoepithelioma was first coined
by Regaud [76] Schmicke [77] independently in
1921. It describes a radio-sensitive tumor. a
varying numbers of lymphocytes were found among
them [64,68,78]. Matching with WHO system, it
includes the WHO 2 and WHO 3 carcinomas. Their
squamous characteristics have been confirmed by
electron microscopy [79,80,81] and immunohisto-
chemical staining employing keratin antibodies
[81,82,83].
Currently, Hsu and associates [84] proposed a
new classification which slightly modified the
WHO's one. In this system, NPC was classified
into four types: keratinizing squamous carcinoma,
spindle cell carcinoma, round cell carcinoma (or
undifferentiated carcinoma), and mixed cell
carcinoma (or non-keratinizing carcinoma). It has
the advantage of providing a better prognostic
correlation, with 5-year survival rates of 21%,
41%, 52%, and 54%, respectively.
D. Possible etiology
The etiology of nasopharyngeal carcinoma is
very likely multi-factorial [85]. Different
factors have been suspected to cause this
particular tumor. They include prior history of
ear, nose and throat diseases, occupational
exposure to fumes and chemicals, cigarette
smoking, ingestion of Cantonese-styled salted
fish, genetical predisposition, exposure to
specific plant products, and Epstein-Barr virus
infection [37,86].
a) Prior History of Ear, Nose, and Throat
TVi senses
Case-control studies have shown a
relationship between nasopharyngeal carcinoma
risk and previous illness of ear, nose and
throat [25,86,87,88]. In Henderson's study
[89], an increased risk of NPC was associated
with recurrent otitis media, sinusitis, nasal
trauma and recurrent tonsillitis. However, no
one can determine whether such an association
is really due to the prior disease or the
medicines used for the illness. In fact, both
kinds of evidence have been found [88,90].
And, of course, the effects may be
synergistic, too.
b) Occupation
Regarding occupations, a higher risk of
nasopharyngeal carcinoma was noted in Chinese
chefs, carpenters, painters, bakers, meat
roasters [57], and people with occupational
exposure to fumes, smoke, and chemicals [89],
People worked under poorly ventilated condi¬
tions in Taiwan also showed a higher NPC
incidence [47]. Unfortunately, these observa¬
tions could not be confirmed in other studies
[24,30,88]. However, it has been proposed
that simultaneously exposure to formaldehyde
and particulates may be a risk factor for NPC
in industrial workers [91]. Moreover, the
tung oil, which is derived from the seeds of
Aleurites fordii and used in paints and
varnishes, possess a strong EBV-activating
capacity [92].
c) Ingestants
Case-control studies in Malaysia, Hong
Kong, Guangdong and Los Angeles [22,23,89,93,
94] found that consumption of Cantonese salted
fish during weaning period could be a risk
factor for NPC. In Hong Kong, a most recent
study showed that the relative NPC risk for
having salted fish as one of the first solid
foods during weaning was 7.5. Moreover, when
comparing those consuming the food at least
once a week to those less than once a month at
age 10 years, the relative risk was 37.7. It
was claimed that over 90% of the young NPC
cases in Hong Kong Chinese could be attributed
to this food item during childhood [941.
In experimental studies, high concentra¬
tion of N-nitrosodimethylamine and other
volatile nitrosamine can be detected in this
Chinese food product [95,96,97,98,99,100].
Since most N-nitroso compounds, including the
N-nitrosodimethylamine, can induce tumors in
the nasal cavity of experimental animals
[101], it is possible that Cantonese-styled
salted fish is tumorgenic. More directly, WA
rats fed with Cantonese salted fish passes
urine with dose-dependent mutagenic activities
[102]. Moreover, Huang and associates found
that after feeding 22 WA rats with such fish
for 12-24 months, five of them developed
carcinoma in the nasal and paranasal regions
[103].
Recently, using gas chromatography,
relatively high levels of N-nitrosodimethyl¬
amine, N-nitrosopyrrolidine and N-nitroso-
piperidine were also detected in Tunisian
stewing base (Touklia), dried mutton preserved
in olive oil (Qaddid), and Greenland dried
unsalted fish [104]. These foods may probably
contribute to the high NPC risk in Tunisia anc
Greenland.
d) Environmental Substances in Nature
Among all the proposed etiological agents
of NPC, Epstein-Barr virus (EBV) may be the
most impressive one. Thus the substances
which can activate this virus may play a role
to the etiology. These agents consist of
haiogenated pyrimidines [105,106], short-chain
fatty acids [107,108], tumor-promoting
phorbol, diterpene esters [109,110], or indole
alkaloids [111]. According to their sources,
they were classified into plant diterpene
esters, microbial indole alkaloids and factors
in human physiological fluids. Based on the
former two groups of EBV activators, Ito had
hypothesized a pathogenesis mechanism for
nasopharyngeal carcinoma [112]:
EBV-activating activities were identified in
two plant families, the Euphorbiaceae and the
Thymeleaceae [111,113,114,115,116]. Since they
were planted along the main roads in southern
China, people living in these areas might come in
contact with the EBV-activating agents by four
routes
1) intake as herbal drugs;
2) inhalation of volatile fractions of the oil;
3) inhalation of the pollens; and
4) inhalation of dust derived from soi
contaminated by such active substances released
from the plants [115,117].
People with preceding nasal illness and
inflammation will provide EBV-carrying lymphocyte
pools to the nasopharyngeal mucosa. These
activating agents, together with the n-butyric
acid produced by Fusobacteriuin and other microbes,
can activate the EBV genome within B-cells. Since
human lymphoid cells with activated early EBV
genes could fuse with cells both with and without
EBV receptors [118], the EBV genome gains access
to the nasopharyngeal epithelial cells. Further
continuous exposure of these epithelial cells to
plant diterpene esters will develop into
nasopharyngeal carcinoma [112].
Although this hypothesis can be
applied both to the pathogenesis of Burkitt's
lymphoma and nasopharyngeal carcinoma, a
detailed data for the distribution of these
plants in all high risk areas is still
lacking. Moreover, EBV receptors is currently
identified in the nasopharyngeal epithelial
cells [119]. The possibility for direct viral
infection to the epithelial cell should not be
ignored.
e) Genetic Factors
In view of the epidemiological studies,
genetic factors seem to play a role in the
etiology of NPC. These evidence include:
1) high risk among Southern Chinese living
under different environmental conditions;
2) elevated risks among peoples who have
genetic admixture with Chinese; and
3) low risk in other racial groups even living
in high risk areas (e.g. Indian in Singa¬
pore).
Family clustering of NPC has been found
in Southern China family [24], Alaskan Eskimo
family [37,120], and in other low risk ethnic
groups [121,122,123,124,125]. Many polymor¬
phic genetic markers have been investigated to
correlate them with NPC risk. Among them, HLA
genes or the major histocompatibility gene
complex on chromosome 6 provide the most
rewarding results.
HLA association has been reported among
Chinese from Singapore [126], Malaysia [127],
Hong Kong [128], People's Republic of China
[129] and California [130]. Among these
Chinese patients, strong association occurs in
A2, BW46, and B17BW58 [131]. In Singapore,
BW4 6 is more frequent in NPC patients age 3 0
or greater and B17 is predominantly found in
those less than 30 [126]. In mid-incidence
populations, the reports are inconsistent.
HLA-A29 is associated with NPC among East
African Blacks. A3, B5 and B15 are among
North African [133]. No specific HLA type can
be found in Tunisians [134]. In low incidence
areas, increased frequency of A3 and B5 can be
seen in German. However, in Australian, only
A3 predominance can be seen [131]. It seems
that genes are important in the pathogenesis
of NPC and some of these genes are associated
with the major histocompatibility complex.
In addition to HLA genes, chromosome
markers have been found in cultured epithelial
cell lines [135,136,137], lymphoblastoid cell
lines, and peripheral blood cells [138]. In
NPC epithelial cell lines, 3q+ marker was
found both in undifferentiated and well
differentiated types [135,136,137]. In NPC
lymphoblastoid cell lines, a giant
submetacentric group A marker chromosome was
found in 3 cases. It was formed by the
translocation of the short arm of chromosome
3, breaking at a point near its centromere, to
the distal band region of the long arm of
chromosome 1 [138]. This finding is analogous
to that seen in Burkitt's lymphoma, another
EBV-associated tumor [140]. In peripheral
blood cells from NPC patients, both the
numerical and structural aberration rates are
higher than control group. The so-called
giant A chromosome exists in lymphoblastoid
cell strains [138] can also be found. This
consistency proposes a general instability of
chromosomes in NPC patients [139].
Finally, genetic predisposition for some
familial NPC patients has been suggested by
higher frequency of in vitro hyperdiploidy in
their dermal fibroblasts [141,142]. However,
more data should be collected before any
conclusions can be drawn.
f) Epstein-Barr Virus
Epstein-Barr Virus (EBV), an oncogenic
[143,144] herpes virus known to cause
infectious mononucleosis [145] and fatal
lymphoproliferative diseases in humans
[146,147], carries both clinical and
experimental data to seriously support its
etiological role in NPC. The characteristics
of this particular virus will be discussed in
the later sessions.
g) Other factors
Beside the factors mentioned above,
ingestion of arsenic also may have a
synergistic action in NPC development [88].
In Taiwan, this heavy metal has been found in
the scalp hair and finger nails of the NPC
patients [149]. However, no other data has
been reported so far. Similarly, case-control
epidemiological studies in Taiwan [48] and
United States [47] suggested an elevated risk
of NPC for cigarette smokers, but studies in
other places fail to reveal such a positive
association. It was suggested by Henderson
[88] that- cigarette smoking only becomes
important when the intensity of smoking was
higher than 20 cigarettes a day [47,149].
III. 1 issue Culture of Nasopharyngeal Carcinoma
Since Old and associates demonstrated the serolo¬
gical relationship between NPC and EBV in 1966 [150],
various workers subsequently found that different
antibodies such as IgAVCA (IgA against viral capsid
antigen), IgAEA (IgA against early antigen), and anti-
EBNA (anti-Epstein-Barr nuclear antigen) could be used
as diagnostic markers for NPC [151,152,153,154]. In
order to further investigate the relationship between
EBV and NPC, numerous workers have tried to establish
permanent epithelial cell line from NPC patients.
However, no successful works have been reported
[155,156,157]. In 1970, de-The and his co-workers
recognized and described four successive types of
growth from NPC explants [158]:
A. Epithelial outgrowth
It lasts for 2 to 12 weeks. Under electron
microscope, desmosomes and cytoplasmic keratin
fibrils can be seen. In early works, no
herpesvirus particles could be found in such kind
of growth [160,161]. However, in 1976, Trumper's
group demonstrated that epithelial explant culture
grew from nude mice expressed Epstein-Barr virus
nuclear antigen (EBNA). Furthermore, by inducing
the cells with bromodeoxyuridine (BUdR),
herpesvirus particles were revealed by electron
microscopy [162]. They could be isolated by using
foetal cord blood [163] or cotton-top marmoset
lymphocytes [164] co-cultivation method.
B. Fibroblastic culture
The fibroblastic culture appears either from
a primary culture or from a secondary growth of
the epithelial cells. They are spindle-shaped,
packed closely, with large oval or round nucleus,
and eventually form monolayer. Under electron
microscope, the colonies show an ultrastructure
intermediate between epithelial cells and fibro¬
blasts [161].
C. Early lymphocytic production
The early lymphocytic production is resulted
from the proliferation and outpouring of lymphoid
cells. It is made up of a heterogeneous popula¬
tion of free floating lymphocytic and mononuclear
cells [158]. No Epstein-Barr viral antigens have
been detected in both fibroblastic culture and
early lymphocytic production [159,160,161].
D. Lymphoblastoid cell line
According to de-The's study [158], about 30%
to 50% of the fibroblastic cultures gave rise to
permanent lymphoblastoid cell lines after 30 to
120 days grown. Under electron microscope,
herpesvirus particles could be identified and they
were claimed to be Epstein-Barr virus by immuno¬
logical methods [158,165,166].
The origin of these cells is very contro¬
versial. Mitsuru and associates [166] found that
inoculation of cell free extracts from EBV
producer lines (P3HR-1 and NPC-204) into fibro¬
blastic cultures could give rise to lymphoblastoid
transformation. de-The suggested that in NPC
biopsies, the lymphoblastoid cells might arise
from the carcinoma cells which underwent dedif-
ferentiation through fibroblasts-like intermedi¬
ates [158]. Vuillaume and co-workers have
suggested the transformation process required a
close cellular contact between the lymphoid cells
and both the epithelial cells and fibroblasts
[161]. However, when EBV was added to lymphocytes
from humans and some non-human primates, lympho¬
blastoid lines could be established [167,168,169,
170,171].
E. Undifferentiated NPC epithelial cell line
Gu and associates had established an undif¬
ferentiated NPC epithelial cell line from a male
Chinese NPC patient [172] whose nasopharyngeal












The cell line established was named CNE-2.
It could be agglutinated by concanavalin-A.
Electron microscopy found that the cells contained
numerous mitochondria, ribosomes, and
polyribosomes whereas the rough endoplasmic
reticulum and smooth endoplasmic reticulum were
scanty. Demonstration of desmosomes and
tonofilaments identified the cell line arouse from
epithelial cells. Like other undifferentiated NPC
biopsies, EBNA could be detected at the 3rd and
10th passage.
F. Well differentiated nasopharyngeal carcinoma cell
line
In 197 6, an epithelioid cell line CNE and a
fusiform cell line CNF were established from a 58-
year old woman with nasopharyngeal carcinoma in
China [173]. She had severe headache, tinnitus,
and epistaxis. A soft tissue tumor mass was
observed on the posterior wall of her nasopharynx.
It was confirmed as a well differentiated squamous
cell carcinoma by tumor biopsy.
During cultivation, the epithelioid cells
emerged first to outgrow around the tissue
fragments on the 10th day. It was until the 12th
passage, the fusiform cells appeared among the
epithelioid cells and gradually increased in
number. Both types of cell could be isolated and
grew independently. On the top of their cell
sheets,, many round cells which represented the
proliferating population could be identified.
Neither lymphoblastoid cell nor fibroblastic cell
appeared during the cause of establishment and by
means of electron microscopy and indirect
immunofluorescence test, no EBV particles or early
antigen could be detected.
In 1982, Gu and associates [174] established
a hypoxanthine-guanine phosphoribosyl transferase
(HGPRT) negative mutant cell line (CNf-A) from the
CNF. This cell line could grow in HAT medium (a
medium containing hypoxanthine, aminopterin and
thymidine which selects for thymidine kinase
positive cells) and resisted to 8-Azaguanine. It
was possible to hybridize it with B95-8 (a
lymphoblastoid cell line derived from infecting
marmoset B-lymphocytes with EBV from a infectious
mononucleosis patient. [175]) to form a EBNA
positive hybrid cell line. The significance of it
is that this is the first human-human hybrid cell
line in China and having the potential to be used
for somatic cell hybridization study.
Another well differentiated NPC cell line was
established from a Hong Kong Chinese male in 1980
by Huang et al [176]. It was called NPCHK1 and
its characteristics will be discussed in the
materials and methods session.
IV. Epstein-Barr vims
A. Morphology
In 1964, Epstein and Barr, and Pulvertaft
simultaneously reported in the same issue of The
Lancet that lymphoblastoid cell lines could be
established from Burkitt's lymphoma explants [177,
178]. Among the thin section of these cell lines,
virus particles which were morphologically similar
to herpesviruses were subsequently identified
[179]. This virus was named Epstein-Barr virus
(EBV) later and was classified as a member of the
gamma herpesvirus family [180].
The diameter of the mature extracellular
particle is about 150 to 180 nm. Its lipoprotein
envelop consists of at least four proteins, with 3
of which are glycosylated. Within the envelop,
the nucleocapsid exhibits icosahedral symmetry and
containing 162 capsomeres. It harbors a large
double-stranded DNA genome [181]. Moreover, like
other gamma herpesviruses, Epstein-Barr virus has
limited host range. It is lymphotropic to B-cells
and conferring upon the cells the ability to grow
permanently in culture.
B. Genome structure
The double-stranded DMA genome consists of
172 kbp, with an organization as TR-U1-IR1-U2-IR2-
U3-IR3-U4-IR4-U5-TR (Fig. 1) [182]. The TR stands
for direct tandem 550 bp repeats [183]; IRl, IR2,
and IR4 are direct 3072, 125, and 103 bp repeats
respectively [184,185]; and IR3 repeats contain
repeat array of GGG, GCA and GGA [186]. Ul, U2,
U3, U4, and U5 are unique DNA domains of 10, 3,
59, 40, and 30 kbp respectively [182].
Restriction endonuclease maps have been derived
[187] and one of them is shown in Fig. 2 [188].
The latent genomes of Epstein-Barr virus is
maintained in a form of circular plasmid in the
tumor cells from Burkitt's lymphoma, NPC,
infectious mononucleosis-derived lymphoblastoid B-
cell lines, and in those derived from in vitro
immortalization of primary lymphocytes [189].
These episomes are formed by linking the TR on
both sides [190] and it is believed that they have
more than one replication origin [191].
Currently, using in situ chromosome cytolo-
gical hybridizations with EBV cloned probes, it
have been shown that the viral DNA can also
integrate into the chromosomal DNA [192,193]. In
Namalwa cell line (derived from African Burkitt's
lymphoma) [194,195], a deletion of more than 15
kbp of cellular DNA has been reported after the
integration [196]. Nevertheless, no oncogene
activation can be confirmed by this process [182].
Since TR is similar to herpes simplex virus
terminal repeat 'a' sequence (both are G-C rich
and bracketed by short terminal direct repeat), It
is possible that these repeat sequences are also
specifically recognized for cleavage and packaging
[197,198,199]. Currently, by using this sequence
as a marker, the clonality of different Epstein-
Barr virus associated tumors was determined [200].
Among the 80 to 100 genes in Epstein-Barr
virus [201], only a few of them are expressed in
latent cycle [202,203]. They include the EBNA-1,
EBNA-2, EBNA-3, the latent membrane protein gene
[204], the EBER RNA genes [205], and the leader
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Figure 1. Epstein-Barr virus DNA. Schematic diagram of linear
virion DNA and of intracellular DNA episomes showing organization
of unique (U) and major tandem repeat (R) DNA domains in relation
to an EcoRI restriction endonuclease map of EBV DNA [181]«
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Figure 2. Map of EcoRI and BamHI restriction sites in the B95-8
Epstein-Barr virus genome shown next to a scale in kilobases
ri87].
C. Epstein-Barr virus-associated antigens
Five types of antigen have been identified in
EBV-transformed cells by immunofluorescence
procedures [208]. Depending on the stage of the





Their respective components are listed in table 1.





EBNA-1 Expressed in all EBV-infected cells
EBNA-2 so far studied and can be used as
E B N A- 3 the marker for the presence of EBV.
E BKI A- 4
E BNA- 5
L Y D MA





Serve as the marker for a cell
entering the viral lytic cycle.
They are not sensitive to DNIA
synthesis inhibitors. A cell that
expresses early antigen is doomed
to complete the lytic cycle,
release infectious virus and die.




Their expression is blocked by
inhibitor of DMA synthesis.
a) Epstein-Barr virus nuclear antigens
These antigens exist in all human cells
transformed by EBV and has been used as an
immunologic marker for the viral DNA. They
can only be demonstrated by anti-complement
immunofluorescence techniques [300,157]. Five
types of Epstein-Barr nuclear antigen (EBNA)
have been detected. Their respective possible
functions and encoding region(s) are
summarized in table 2.
TABLE 2. CHARACTERISTICS OF DIFFERENT
EPSTEIN-BARR NUCLEAR ANTIGENS
EBNA-1 (Mff= 65- 75 kilodalton)
Encoding region : BamHI-K rightward reading frame 1
( B K R F 1) [211,212] plus an exon frorr
BamHI-E [213].
Possible function : A sequences-specific DKlA-binding
protein whic h binds to the E B V origin
of replication (ori-P) and supports
replica-tion of plasm id containing
ori-P [214,215,216,217].
EBNA-2 (MW= 80- 90 kilodalton)
Encoding region : BamHI-Y rightward reading frame 1
(BYRF1) [218] plus B a in H I- U, H fragment
[206,219,220]. The transcription of
EBNA-2 gene is initiated in the BamH I-
U fragment. It is spliced later and
that all of the EBNA2 is encoded
within the continuous long open
reading frame in the BamHI-Y and H
fragment [221].
Possible function: Involved in the initiation of virus-
induced B-c 6 I I transformation [222,
223] and plays a role in determining
the cellular growth phenotype [224].
EBNA-3 (MW= 140 kilodalton)
Encoding region: BamHI-E right ward reading frame 1
(BERF1) encoded at least part of this
protein [225,226,227,228].
Possible function: Bound to double and single-stranded
DBA [229]
ERNA-4 (MW= 148- 180 kilodalton}
Encoding region : Probably a BERF1- related open readinc
frame, BERF-2b [225].
Possible function: Bound to double and single-stranded
DBA [229].
EBNA-5 (MW= 22- 70 kilodalton)
Encoding region: Exons from BamHI-W, Y, H fragment
[ 23 0] and probably plus part of the
open reading frame from BERF, the
BERF-4 [226].
Possible function: not known.
b) Lymphocyte determined membrane antigen (LYDMA)
Little is known about this group of
antigens. In general, LYDMA can be detected
by cytotoxicity assay, growth inhibition assay
[208] and leukocyte migration assay [231].
Like other virus-induced antigens, the T-cell
response to this antigen is HLA restricted
[232]. Currently, a membrane associated
protein encoded by the U5 region of EBV DMA
was identified by Fennewald et al [233]. The
relationship of this protein to LYDMA is being
determined.
c) Early antigen (EA)
They are the protein complexes which
expression are independent of the presence of
viral DNA synthesis inhibitors. Different
enzyme activities have been reported to
associate with them. They include protein
kinase activity [234], DNase activity [235],
virus specific DNA polymerase activity
[236,237], endonuclease activity and thymidine
kinase activity [238]. By using monoclonal
antibodies, protein with molecular weight from
47 to 60 kilodalton (kd), 85 kilodalton, and
140 kilodalton was found to associate with
them.
The 47 to 60 kd complex is mainly in the
nuclei whereas the 85 kd protein appears in
the cytoplasm of the infected cells, often in
a granular or fibrous pattern [238]. Since
the antibody against the former polypeptide
reacts with both acetone and methanol-fixed
cells while the 47 to 60 kd complex has been
classified as a component of the diffuse-type
early antigen (EA-D) whereas the 85 kd complex
as a component of the restricted-type early
antigen (EA-R).
Preliminarily, the 47 to 60 kd protein
have been mapped to the BamHI-M fragment of
the EBV DNA [239] while the 85 kd protein is
mapped to the BamHI-H fragment [240]. Since
discrepancy has been encountered in deter¬
mining the encoding sequence of the early
antigen complex, requirement for intergenomic
interaction has been suggested for the
expression of these early antigens. In fact,
similar type of interaction was reported by
Takaki et al. [241] and Takada et al [242].
The function of these early antigens are
not very clear. They may be involved in the
early stages of viral DNA replication.
Moreover, Bayliss and Wolf [243] found that
Epstein-Barr viral early protein, which did
not belong to the membrane type, could induce
cell fusion. This might provide the route for
EBV to infect cells without the EBV receptor.
d) Membrane antigen
In early days, it was not always clear to
what extent early studies on membrane antigen
involved the early type (E-MA) or the late
type (L-MA). Immunoprecipitation studies have
suggested that at least one early membrane
antigen-associated polypeptide exists. This
polypeptide has a molecular weight 90
kilodalton [244,245], probably acts as a
structural component of the virion. Anti-EMA
antibodies have been found to mediate
antibody-dependent cellular cytotoxicity
(ADCC) against superinfected Raji cells [246].
It may also serve as a target for natural
killer (NK) cells [247].
More studies have been done on late
membrane antigen (L-MA). They are expressed
in the membrane of viable lymphoblastoid cells
[208] or expressed in the envelops of mature
virus particles [248,249]. These antigens are
responsible for the induction of neutralizing
antibodies [250]. At least, three glycopro¬
teins have been identified to compose this
complex [251,252,253,254,255]. They are
designated as gp300350 (glycoprotein with a
MW of 300-350 kd); gp200250 (glycoprotein
with a MW of 200-250 kd); and gp8590
(glycoprotein with a MW of 85-90 kd) [209].
All of them are highly glycosylated, namely
over 50% composed of carbohydrate [256], The
gp300350 and gp200250 are closely related
since monoclonal antibodies have been produced
to recognize both of them [257,258]. However,
at least two other monoclonal antibodies have
been produced to react with gp300350 only
[259,260].
The gp300350 and gp200250 are found to
be encoded by the BamHI-L fragment of EBV DNA
[261]. In the viral envelop, membrane
antigens are suggested to be responsible for
binding the virion to receptors on the target
B-lymphocytes [239]. Since these antigens
contain the antigenic determinants for
neutralizing antibodies and are capable of
giving rise antibody-dependent cellular
cytotoxicity (ADCC) [262], they are being
used as the base for developing the vaccine
against Epstein-Barr virus [263].
ei Viral capsid antigen (VGA)
Conventionally, viral capsid antigen (VCA)
is detected by immunofluorescence cest using
human sera. By usincj monoclonal antibodies
[257,258,259,261,263,264,265,266], it was
found that VCA-immunofluorescence test
measures antibodies directed against membrane
antigens as well as those antigens associated
with viral capsid.
In the major VCA complex, it contains
proteins with molecular weight of 125, 152,
and ISO kilodalton. Preliminary results show
that the 160 kd protein is encoded by BamHI-C
fragment while BamHI-A fragment encoded the
125 kd protein [237]. The former protein is
non-glycosylated. It is the major polypeptide
in solubilized EBV nucleocapsid [267] and is
found mainly in the nuclei of infected cells
[268]. The 125 kd protein is glycosylated and
can be found in both cytoplasm and nuclei of
virus producing cells [265], These two
polypeptides can be detected only when no
viral DNA synthesis inhibitor exist in the
culture medium.
Although 160 kd protein might represent
the major component of viral capsid, the 125
kd protein play an immunogenic role following
primary EBV infection [237].
V. Epstein Barr virus and nasopharyngeal carcinoma
A. Relationship between WHO 2 3 npc
a) Serological markers for EBV association
Numerous studies have been carried out to
confirm the association between NPC and EBV-
specific antigens including viral capsid
antigen (VCA) [268], membrane antigen (MA)
[269], early antigen (EA) [270], EBV-
associated nuclear antigen (EBNA) [210],
antibody-dependent cellular cytotoxicity
(ADCC) antigen [271], and lymphocyte-defined
membrane antigen (LYDMA) [272,273]. Now, it
is known that patients beyond the- initial
stage of this tumor generally show high titres
of IgG and IgA antibodies to the EBV capsid
antigen (VCA) and to the EA-D [153,274,275,
276,277,278,279,280]. This is true not only
in Asian and African patients but also in
American, Eskimos of Greenland and Alaska,
Malaysian, and Swedish NPC patients [37,281,
282,283,284,285].
The anti-VCA titres in NPC patients are
found, as a rule, to be 8 to 10 times higher
than controls [275,279,286,287,288,289,290,
291]. For anti-EA complex, the anti-D is the
dominant antibody. Its incidence and titres
also increases with the total tumor burden and
decreases following successful therapy [280].
Another outstanding feature of NPC patient
is the high levels of IgA antibody. This
feature was first observed by Wara et al
[292]. Soon after, many workers have shown
that such IgAs are directed against the VCA as
well as the EA-D [153,293], Intensive studies
have been conducted in China to evaluate these
IgAVCA and IgAEA antibodies as markers for
NPC early detection [293,294,295,296,297].
For one of these studies in Zang-Wu County,
14 8, 02 9 people aged 3 0 and over were screened
for IgAVCA by immunoenzymatic test during
1978 to 1980 [293], 3,533 (2.4%) of them were
found to be positive. Among these persons,
460 individuals with IgAVCA titres equal to
or greater than 180 were examined clinically.
55 cases were histologically diagnosed as NPC
(represented 1.55% of the IgAVCA positive
individuals). Follow up other 3,478 positive
persons for 1 to 3 years, 32 further NPC cases
were detected( 10 in stage I, 9 in stage II,
11 in stage III, and 2 in stage IV) [295].
In fact, people with IgAVCA titres increased
from four-fold or more had a 18.5% chance for
getting NPC. Thus follow up the individuals
with increased IgAVCA titres, one out of five
would eventually develop NPC within three
vears.
In Wu Zhou city, another study was done
for 12,930 persons [282]. 680 of them were
IgAVCA positive while 30 persons were found
IgAEA positive. Among these persons, 13 NPC
cases were detected in the former group and 9
cases were found in the later group. It shows
that compared with IgAVCA antibodies, IgAEA
antibodies is a more specific marker for NPC.
However, its lower sensitivity hampers it from
being used as the potential screening marker.
Recently, Pi and associates have developed an
ELISA test to increase the sensitivity for
IgAEA screening [298]. Its application to
population survey is still proceeding.
The possible reason for the elevation of
IgA antibodies in NPC patients is unknown. It
was reported by Gregory and associates [299]
that IgA antibodies could block the antibody-
dependent cellular cytotoxicity reaction
(ADCC) mediated by IgG antibodies in NPC
patients. Since ADCC has been found to be a
possible immune defense mechanism against
infectious agents, the elevation of IgA
antibodies in sera might be detrimental to
patients rather than beneficial [299]. This
may explain why NPC patients with high ADCC
titre at diagnosis appeared to indicate a good
prognosis [300,301,3 021.
Another evidence for EBV association with
undifferentiated and poorly differentiated NPC
comes from the regular detection of EBNA in
the tumor biopsy specimens [156,157,303,304,
305,306,307]. The details of these antigens
have been mentioned previously. In addition
to anti-complement immunofluorescence test
(ACIF) [210], EBNA can be detected by anti-
complement immunoenzymatic test [305]. This
method was found to be as sensitive as ACIF
and was more convenient to perform.
Recently, an EBV-specific DNase is demon-
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1. superinfection of Raji cells with thE
virus; and
2. treated D98HR1 cells or a few lympho
blastoid cell lines with 5-iodo-2'-
deoxvuridine CIUdRl [235,3061.
This specific DNase can be neutralized b}
sera from NPC patients, but not from most
healthy individuals [307,308,309,310,311]. Ir
a larger survey conducted in Taiwan recently
[312], taking the neutralization of 2 units of
DNaseml serum as cut off, the specificity and
sensitivity of detecting this antibody in NPC
patients was found to be 94.7% and 90.3%
respectively. Thus the antibody against EBV-
specific DNase also carries the potential to
serve as a NPC marker.
b) Electron microscopic studies
Throughout the years, numerous electron
microscopic studies have been done on NPC
using fresh biopsies and transplanted
nasopharyngeal tissues. The results revealed
either no viral particles [79] or contained
virus-like particles [313,314,315]. Among the
virus detected, they were either similar to
EBV at least in terms of diameter and
morphology [314] or had a great morphological
similarity to coronaviruses [315]. These
confusions were also seen in immunological
studies, that is the patients sera contained
antibodies against EBV as well as against
coronavirus [315]. So far, it has not been
possible to demonstrate typical EBV particles
in NPC tissues as shown by Epstein and Achong
in cell cultures of Burkitt's lymphoma [179].
This may be explained by the lost of
morphological configuration of the DNA virus
during incorporation into the host DNA [316].
Alternatively, it may be due to the fact that
EBV-carrying NPC tumor cells in vivo are
mostly non-producer [317,318] so that they can
hardly be detected by electron microscopy.
In Trumper and associates studies [162,
163], treated the NPC cells with bromo-
deoxyuridine (BUdR) (or iododeoxyuridine,
IUdR) or nude mice transplantation could
induce the viral lytic cycle thus EB-like
particles could then be seen under electron
microscope. These viral particles were biolo¬
gically active in infecting and transforming
foetal cord blood lymphocytes [163].
Moreover, testing the tumor cells by immuno¬
fluorescence method, VCA could be detected.
c) Detection of EBV genome
In the past, the presence of EB viral
DNA was believed to be reflected by the
expression of EBNA. However, according to
Henle and Henle [319], the anti-complement
immunofluorescence technigue [210] used to
detect EBNA in touch preparations has several
pitfalls: Firstly, there may be no tumor
cells deposition on the slides. Secondly,
non-specific antinuclear antibodies (ANA) are
freguently found in the sera from tumor
patients. They may gain access to the nuclei
of the deposited cells [319] and inducing the
EBNA-like staining [320]. in view of this,
detection of viral DNA directly in tumor
tissues by DNA hybridization techniques
becomes a trend.
Since the works done by zur Hausen [320],
multicopies of EBV DNA have been regularly
found in WHO 2 and WHO 3 NPC biopsies,
including patients from China, Singapore,
Alaska, Greenland, Sweden, German, the United
States and other countries [281,304,323,324,
325,326,327,328,329,330,311]. By using in
situ hybridization [156,332], it is found that
the viral genome locates in the carcinoma
cells rather than in the infiltrating
lymphocytes. However, there is no correlation
between the number of EBV genome equivalents
and EBV antibody titres [327,333].
In 1983, Raab-Traub and associates
reported transcription of EBV DNA in NPC
biopsies [334]. Nevertheless, normal naso¬
pharyngeal cells were also found to encode EBV
RNA [335]. In general, the virus-specific
small RNAs were not present in normal naso¬
pharyngeal tissues but were present in the NPC
biopsies.
B. WHO 1 nasopharyngeal carcinoma
a) Serological profile
In contrast to WHO 1 and 2 NPC, WHO 1
NPC (the squamous cell carcinoma) patients
show no significant rise in anti-VCA, anti-MA
or anti-EA titres [15,274,277,283]. Also in
the three well differentiated NPC cell lines
[159,176], no EBNA or early antigens could be
detected. Parallel electron microscopic
studies revealed no viral particles, too.
b) Detection of EBV genome
It has been claimed that EBV DNA can not
be demonstrated in WHO 1 NPC [322, 336].
However, in the study by Anderson-Anvret and
associates [322], 2 of the 4 undifferentiated
NPC with some signs of squamous differentia¬
tion contained an average of two EBV-genome
copies per cell.
In 1983, Raab-Traub and her co-workers
[334] reported transcription of EBV DNA
fragments (BamHI-H, B, K, Y, Bl, II, A, and
EcoRI-F and GZ) in a well differentiated NPC
biopsy. It is of interest that the trans¬
cription pattern represented a state of
abortive infection not stimulated by any of
the in vitro systems. Unfortunately, no other
similar result has been published.
Currently, 5 more WHO 1 NPC biopsies were
found to contain very low copy number of EBV
DNA [337]. However, no one can tell whether
the EBV signal came from the tumor cells or
the infiltrating lymphocytes.
VI. Epstein-Barr virus and other tumors
A. EBV-associated lymphomas
a) Burkitt' s lymphoma
Burkitt's lymphoma is a malignancy of B
cells [338], In Africa, it is the most fre¬
quent tumor affecting children, with an
incidence in endemic regions as high as 10
cases per 100,000 per year, and with boys
being about 2.5 times as often afflicted as
girls [339]. It shows an incident peak
between 6 and 8 years, with no patients under
1 year and only few over 18 years of age.
Histologically, Burkitt's lymphoma is descri¬
bed as a poorly differentiated lymphocytic
lymphoma [340,341] comprising a monomorphic
outgrowth of undifferentiated lymphoid cells
with uniform size and shape. Since the tumor
cells are interpersed with large foamy
histiocytes, under light microscope, they are
described to exhibit a starry-sky pattern
[341]. Based on the studies of glucose-6-
phosphate dehydrogenase, and immunoglobulin
determinations [342], this tumor has a mono¬
clonal origin.
For EBV-specific antibodies, Burkitt's
lymphoma patients develop substantially higher
titres of antibodies to VCA, namely 5- to 10-
time higher than age-, sex-, and tribe-matched
control children, siblings, and other family
members, or pediatric patients with other
malignancies [343,344,345]. In contrast to
NPC, the majority of the patients also develop
antibodies to EA-R [278,346], often at titres
close to or exceeding the anti-VCA [347].
Antibody titres to EBNA range from below to
well above the levels observed in controls
[346,347]. Moreover, antibodies to EBV-
specific cell membrane antigens and antibody-
dependent cellular cytotoxicity tests also
cover a wide range of titres [348,349,350],
In EBV DNA studies, Burkitt's lymphoma
cells have been found to harbor EBV DNA in
amounts equivalent to multiple genomes per
cell [320,323,327,328,345,351,352,353,354].
They exist in both circular episomal form and
in linear form integrated into the cellular
DNA [355].
Intensive works have been done on the
pathogenesis of this disease. For both
endemic and sporadic cases, Burkitt's lymphoma
is found to associate with specific chromo¬
somal translocations that result in the juxta¬
position of the c-myc locus on chromosome 8
and various immunoglobulin (Ig) loci located
on chromosome 14, 22, or 2 [356,357,358,359,
360,361,362]. These translocations are
thought to lead to the deregulated expression
of the c-myc gene [363,364] because of
structural alterations present in the 5'
regulatory portion of the translocated gene
[359,362,365,366] and possibly, the influence
of various transcriptional regulatory elements
from the Ig loci [363].
Although deregulated expression of the c-
myc gene is thought to play a pathogenic role
in Burkitt's lymphoma and in analogous B cell
tumors in several animal species [367,368],
both in vitro experiments involving the
transfection of an activated c-myc gene into
murine B lymphocytes [369] and in vivo
experiments involving transgenic mice carrying
activated c-myc genes in their B cells
[370,371] indicate that c-myc activation per
se does not lead to transformation. So
additional alterations are reguired for tumor
development. Indeed, it has been recently
shown that EBV infection of an EBV-negative
Burkitt's lymphoma results in increased
expression of the endogenous cellular oncogene
fgr [372]. Although increased concentration
of c-fgr mRNA alone also cannot induce malig-
nant transformation in normal lymphocytes,
this evidence at least suggests that Burkitt's
lymphoma is resulted from a multi-step process
involving. the alteration of several genetic
elements.
b) Immunodeficiency-associated B-cell lymphomas
B-cell lymphomas can arise at a higher
frequency in immunological compromised indivi¬
duals [373,374,375,376]. Similarly, they
emerge in the wake of primary infections or
following activation of the persistent latent
EBV carrier state. It stands to reason,
therefore, that immunodeficiencies should
influence, for better or worse, EBV-assaciated
disease processes [377]. In fact, it is found
that most fatal infectious mononucleosis
cases, if not caused by mechanical factors
such as airway obstruction or splenic rupture,
can be attributed to failure of appropriate
immune response [378,379,380,381,382,383].
According to the cause of these immunodefici¬
encies, the EBV-associated B-cell lymphomas
are discussed as follows:
1. Genetic immunodeficiencies
i. Lymphoma in X—linked lymphoproliferative
syndrome (XLP)
XLP results from an inherited defect
of the X-lymphoproliferative control
locus. Since these patients are unable
to handle primary EBV infection [384,385,
386,387,388], aproliterative and lympho¬
proliferative disorders invariably
appear. The aproliferative expressions
consist of acquired agammaglobulinemia,
agranulocytosis, red cell aplasia, and
aplastic anemia. The lymphoproliferative
phenotypes consist of chronic or. fatal
infectious mononucleosis, pseudolymphoma
and malignant B-cell lymphoma [389].
Among all the patients with XLP related
lymphoma, one third of them also exhibit
infectious mononucleosis before the neo¬
plasm is evident. It was proposed by
Purtilo and associates [389] that
individuals with XLP who had mild immune
deficiency to EBV tended to develop the
malignant lymphoma while those unable to
restrain the polyclonal B-cell prolifera¬
tion developed infectious mononucleosis.
Characteristically, the malignant
lymphoma are extranodal and located
predominantly in the terminal ileum,
viscera, or central nervous system [385],
Since the EBV-specific antibody responses
are lacking or less than expected in a
primary EBV infection, detection of
heterophil antibodies, EBV DNA and EBNA-
positive lymphoid cells in the lymphopro-
liferative lesions has served to
establish the diagnosis [386,387,388,390,
391].
ii. Lymphoma in ataxia-telangiectasia (A-T)
In these patients, they have no
difficulty in handling primary EBV
infection. The anti-VCA titres are
within or somewhat above the normal
range. Enhanced incidence of antibodies
against EA-R and VCA have been noticed
but anti-EBNA is absent [392,393,394].
Since T-cell deficiencies of varying
degrees of severity has been found in
these patients, T-cell action is possibly
required for EBNA expression [395]. A B-
cell lymphoma arouse from A-T patient has
been reported to be EBV DNA positive
[396]. Its genome equivalent is compara-
ble to NPC and Burkitt's lymphoma
patients (about 53 EBV genomes).
However, no studies have been done about
its clonality.
iii. Others
In addition to XLP and A-T patients,
EBV is also suspected to cause lymphopro-
liferative diseases or lymphoid tumors in
Chediak-Higashi syndrome [398,399] and
severe combined immunodeficiency, two
other congenital immunodeficiencies.
However, more studies should be done to
confirm the association with EBV.
2. Iatrogenic immunodeficiencies of organ
transplant recipients
Among the renal, cardiac, hepatic
or bone marrow allograft recipients, an
enhanced risk for developing de novo
cancers has been noticed [375,400,401,
402]. The most commonly seen are lympho-
reticular malignancies closely resembling
non-Hodgkin's lymphoma [401]. The risk
for neoplasm development in these
patients various with the immunosuppres¬
sive regimen employed and with the nature
of the allograft.
A considerable amount of evidence
has been found in allograft recipients to
implicate the EBV as a causative agent of
these transplant-associated lymphoreticu-
lar tumors. They include:
1) increased shedding of EBV in the
patients' oropharynx [403,404];
2) significant elevations in antibody
titres to EBV following transplan¬
tation [405,406]; and
3) demonstration of EBNA or EBV genomes
within the cells that comprise the
tumors [390,391,407,408,409,410].
The tumors developed by- these
patients are unusual compared with those
B-cell lymphomas arising in non-
immunosuppressed patients. They present
frequently as localized extranodal
lesions, with a high frequency of central
nervous system (CNS) involvement [400,
411,412], and are reversible following a
reduction or complete withdrawal of
immunosuppressive agents [408,413,414,
415,416,417]. Histologically, they are
compatible with non-Hodgkin's lymphoma of
the large-cell type (diffuse histiocytic
lymphomas) frequently with immunoblastic
features [418,419]. However, variations
have been seen in other studies [420].
The lymphomas can arise as a direct
consequence of primary EBV infection,
acquired naturally or via blood from
seropositive donors [407,420,421,422,
423], or develop after activation of the
latent viral carrier state [407,421,424,
425]. Unfortunately, EBV serology cannot
discriminate between who will and will
not develop lymphomas [320], Although in
most of these lymphomas contained EBV DNA
or EBNA-positive cells, occasional biopsy
has been encountered in which EBV nucleic
acids or protein products cannot be
detected [410]. It indicates that at
least some cases of lymphomas may arise
spontaneously from immunocompromised
host.
In the past, relying on cellular
immunoglobulins studies, unlike spon¬
taneous B-cell lymphomas [426,427], only
occasional transplant-associated tumors
were reported to be monoclonal in origin
[422,428], Recently, detecting the
immunoglobulin gene rearrangement by
southern blot hybridization [429] have
found that most lymphomas tissues from
cardiac, hepatic, renal and bone marrow
allograft recipients show a multiclonal
phenomenon [410, 430]. That is when
biopsy tissues are sampled from several
sites of a patient, each has a different
proliferating clone of tumor cells
(showing different Ig gene rearrangement
pattern). Multiclonal is different from
polyclonal tumors in that no coexisting
of two or more types of Ig gene
rearrangement can be found at a single
site.
In a recent study of a 12-year-old
child with bone marrow transplantation
[422], except for existence of multi¬
clonal lymphoma in the bowel and lung
lesions, DNA extracted from thymus,
liver, spleen, appendix, and retroperi¬
toneal lesions showed oligoclonal B-cell
proliferation. In these cells, a set of
faint bands at varying positions within
the autoradiogram was noticed. It
indicated that no predominant clonal
population of B lymphocytes were present
but instead, a number of minor B cell
clones existed. These results provide
molecular evidence to support the three
step hypothesis of EBV-induced B-cell
lymphomas proposed by Klein [431]:
Step 1: initiation and immortalization,
usually (but not always) by EBV, of
preneoplastic B cells, capable of
continued division;
Step 2: promotion of B-cell division and
possibly, interference with normal
differentiation of long-lived latent
preneoplastic B cells;
Step 3: a selective emergence of a
single clone with cytogenetic defect.
In the child, the multiple faint
rearranged bands might indicate the
initial emergence of dominant B cell
clones from a polyclonal mass of
proliferating B lymphocytes. In the more
advanced stage as in the bowel, an
overwhelming clone of B cells dominant
the lesions.
c) B cell lymphomas in disease—related immuno¬
deficiency
A large variety of diseases have immuno¬
suppressive effects. Among them, only B-cell
lymphoma arouse from acquired immunodefi¬
ciency syndrome (AIDS) associates with primary
EBV infection or activation of the EBV carrier
state. These lymphomas are Burkitt's
lymphoma-like histopathologically [164,432,
433]. Biopsies from 2 cases have been shown
EBNA-positive [434]. They are monoclonal in
origin and at least some of them show 8;14 or
8;22 translocation [432,433].
d) B-cell lymphoma at immunological privileged
sites
One out of two patients with primary
central nervous system lymphoma has been found
to contain 2 EBV genome equivalents per cell
in a study [424,434]. The patient is a 48-
year-old man. Computerized tomography
revealed a mass in the posterior fossa, which
at surgery was found to be a necrotic large-
cell histiocytic lymphoma bearing cytoplasmic
immunoglobulin of IgM type. No detectable
antibodies to EBNA was found thus a recent
primary EBV infection was suggested. In
addition, Sera from four other primary CNS
lymphoma patients revealed anti-EA-R titres
similar to those in Burkitt's lymphoma
patients (1:40 to 1:320) [435]. However, more
studies should be done to confirm the role of
EBV.
e) Other carcinomas of the head and neck region
During studying NPC, numerous head and
neck tumor patients with carcinoma outside the
nasopharynx have been used as controls.
Examination of such tissues for EBV DNA or
EBNA-positive cells yield, with few exception,
negative result [303,320,321,326,328,435],
Serological findings showed that the IgG anti-
VCA titres are elevated compared with healthy
controls, although are by no means comparable
to that seen in NPC. Moreover, low titres of
IgG anti-EA-D andor IgA anti-VCA can also be
seen in some cases [151,284,326,436]. By
using DNA hybridization techniques, more
tumors other than NPC and Burkitt's lymphoma
have been found possibly associated with EBV
infection. Their DNA and serological profiles
are summarized in table 3.
J ABLE 3.—TUMOUR TISSUES WITH DETECTABLE EBV GENOME OTHER THAN
NPC AND VARIOUS LYMPHOMAS
Tissue Type Cases Serological Profile DNA Study Ref.
no.
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VII. DNA Hybridization
Due to the works of Watson and Crick, DNA is now
known to be a double—stranded molecule held together by
hydrogen bonds between the purine and pyrimidine bases
of the respective molecules [443]. When two single-
stranded nucleotides with similar base sequence are
incubated together, they will hybridize with each other
to form a duplex. Using this characteristics, the DNA
hybridization technique is devised and has been using
to study the gene structure and function for nearly two
decades. Subject to the objective of the experiment,
hybridization can be carried out in solution or on
solid support.
A. Reassociation kinetics
In solution, the analysis are called
reassociation kinetics or renaturation kinetics.
As its name implied, it is based on the ability of
single-stranded pieces of DNA to reassociate with
its homologous DNA. Under constant conditions,
the rate of formation of double-stranded molecule
is a function of the concentration of the
reactants. To test DNA for the presence of viral
sequences, one can compare the rate of
hybridization of a small amount of viral DNA with
itself in the presence of control DNA to the rate
of hybridization with the same concentration of
viral DNA in the presence of test DNA (for review
see ref. 444).
Although the solution hybridization is the
standard method for quantitative measurements of
sequence complexity and composition, there are
practical difficulties when the number of samples
is large. Moreover, the DNA quantity needed is
also very large. Nowadays, tendency has shifted
to use filter hybridization or in situ hybridiza¬
tion.
B. Filter hybridization
This technique involves immobilization of
denatured DNA onto a solid support including
nitrocellulose, nylon, and chemically-activated
papers. The respective characteristics of these
filters are listed in table 4. After the
immobilization, self-annealing is prevented and
the bound sequences are available for hybridiza¬
tion with an added nucleic acid probe.
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This method was developed by Kafatos et al
[445]. It involves direct spotting of
multiple DNA samples on nitrocellulose filter.
Radioactive DNA probe is hybridized to it to
test for the presence of homologous sequences.
Since this method is easy to perform and large
amount of samples can be screened at the same
time, it is particularly suitable for
screening viral genome in clinical samples
[446].
Recently, this technique has been used to
detect specific mRNA in animal cells or
tissues [447,448]. The quick-blot method
suggested by Bresser and associates showed
that following cell lysis and proteinase K
digestion, mRNA could be immobilized on
nitrocellulose filter after solubilizion in
Nal. Further acetylation of the residual
proteins with acetic anhydride would leave a
mRNA bounded nitrocellulose filter. It is of
interest that the immobilized mRNA could also
serve efficiently as a template for protein
synthesis, DNA synthesis, and released from
the filter for further manipulations [448].
b) Southern blot hybridization
Since it was established by Southern in
1975 [449], lots of improvement have been
suggested. Classically, this technigue can be
divided into 4 parts:
1. restriction enzyme digestion of the nucleic
acids;
2. separated them by electrophoresis;
3. transfer the fragments to the nitrocel¬
lulose filter by a buffer driven system;
4. hybridization (including prehybridization,
hybridization and stringency washing of the
filter) and;
5. autoradiography of the nitrocellulose
filter.
Recent improvement in this field include
fractionation of DNA restriction fragments by
ion-exchange chromatography [450,451]. hybri¬
dization of labeled DNA to DNA in agarose gel
directly [452], using electro- [453] or vacuum
driven transfer technique [454] instead of the
classical buffer driven one, use of synthe¬
sized oligonucleotide probe [455] and more
sensitive RNA hybridization probes [456,457,
458], development of more sensitive hybridiza¬
tion techniques (such as sandwich [459] and
indirect sandwich hybridization techniques
[460]), and replacing the 32p label with a
non-radioactive one.
Among the non—radioactive labeled probes
used, biotin-labeled analogues of deoxyuridine
triphosphate and uridine triphosphate was the
first ones to achieve widespread use. In
these probes, biotin is covalently linked to
the C5 position of the pyrimidine ring through
an allylamine linker arm (Fig. 3) [461].
After hybridization, these biotinylated probes
are generally detected by making use of the
affinity of avidin (or streptavidine) for
biotin, followed by conjugates of avidin or
antiavidin antibodies with enzymes, fluore¬
scent groups or heavy metals.
At the moment, many studies employ a
strepavidin-biotinylated complex containing
either peroxidase or alkaline phosphatase.
However, most studies with such probes report
a 5- to 10-fold less sensitive than an
equivalent 32P-labeled probe [462].
Recently, a technique has been developed
to label nucleic acid with a hapten. Tchen
and associates [463] found that guanine
residues in nucleic acids could be labeled
with N-acetoxy-N-2-acetylaminofluorene (AAF)
and its 7-iodo (AAIF) derivative (Fig. 4). By
using an immunochemical sandwich-type assay,
the hapten-labeled probe attached to the
sample DNA could be detected by an hapten-
specific antibody labeled with an enzyme or
fluorescent dye.
Almost at the same time, Renz and Kurz
[464] also described a method which allowed
crosslinking of a particular enzyme (such as
peroxidase and alkaline phosphatase) with
single stranded DNA. These probes made it
possible to detect the hybrid directly by only
addition of the substrate at the end of the
hybridization period. It shall be of interest
to see whether this approach can be developed
in routine diagnosis use.
Figure 3, Attachment of biotin to nucleic acid, utilizing linker














r-ribosyl or r-deoxyribosyl; R2= H (AAF) or I (AAIF)
Figure 4. The hapten M-acetoxY-N-2-acetylaminof luorene (AFF) and
its 7-iodio derivatives [462].
Compared with dot blot hybridization,
Southern blot is less sensitive. Using EBV
BamHI-K as probe, it was found by Andimen and
associates [424] that dot blot hybridization
was about 10-fold more sensitive than
Southern. This difference may be due to the
DNA losses incurred in the transfer of DNA
from the gel to nitrocellulose. Moreover, in
dot blot method, both degraded and intact
sequences contribute to a single concentrated
hybridization signal. This fact is certainly
also explains its higher sensitivity [465].
However, in order to gain more information
about the fragment of interest such as its
molecular size, only Southern blot technique
can serve the purpose.
Finally, when both techniques are used to
detect viral genome in tissues, one common
limitation of them is that neither method is
able to distinguish whether all of the cells
have a low genome number or only small amount
of cells with high genome equivalents exist
among many uninfected ones. Fortunately, this
problem can be solved by in situ hybridiza¬
tion.
c) In situ hybridization
In this technique, hybridization of a cDNA
or cRNA probe to nucleic acids is performed in
cytologic or histologic preparations, either
frozen or formalin-fixed-paraffin embedded.
One great advantage of it is the ability to
localize virus-specific sequences to a
particular cell type. Moreover, it can also
detect viral nucleic acid in a few cells among
a broad innocent background. Many workers
have reviewed the technical aspects of this
method [466,467]. The major difficulty
encountered in this technique is how to fix
and pretreat the cells so as to maintain their
X.
integrity, yet allow access of the probe.
Moreover, the size of the probe is critical.
Usually, 70 base pairs of size will give
optimal hybridization efficiency [468,469].
Generally, 32P-labeled probes are not
used as the signals produced are too diffuse.
3H is still the most sensitive and precise
label but normally a long exposure times is
required. In this case, 35S-labeled probes
should give satisfactory results especially if
a rapid result is required.
In diagnostic pathology, in situ hybri
dization has been used for:
1. localizing viruses involved in specific
infection, such as Epstein-Barr virus
[470], human papillomavirus [471] etc.;
2. characterizing neuroendocrine tumors by
localization of gene products for specific
hormones [472];
3. localizing gene products for amplified
oncogenes or growth factors in neoplasms
[473,474]; and
4. mapping protooncogenes on chromosome [475].
Although this technique is useful, some
inherent problems still exist. It was
suggested by Wolf and associates [476] that
partial evaporation of solvent or non-specific
binding of the probe might in some experiment
mimic positive result. Confirmation of the
result simultaneously with other independent
hybridization method is recommended.
MATERIALS AND METHODS
I. Cell lines and tissue culture
A. NPCHK1
It is a cell line derived from a well
differentiated NPC. The clinical history of the
patient had been described [176]. Tissue taken
from the tumor was cultured for over one year.
Afterwards, it was frozen down until being used in
my experiments The characteristics of the cell
line are summarized as follows:
1. with cell doubling time as 28+ 2 hours;
2. xenotransplantable and the transplants showed a
histological feature similar to the original
biopsy;
3. chromosome showed both numerical and structural
aberrations;
4. negative for EBNA;
5. negative for EA after lUdR induction; and
6. failed to be infected with EBV from P3HR-1 and
B95-8 cells;
Under phase contrast microscope, the cells in
monolayer are polygonal in shape. Many round
cells are mounted on the top of the cell sheet
(Fig. 5, Fig. 6). Under electron microscope,
tonofilaments and desmosomes are visible in both
types of cells, thus showing the typical features
of squamous differentiation.
The medium used to culture NPCHK1 was RPMI
1640 (GIBCO Laboratory) supplemented with 100
IUml penicillin plus 100 ugml streptomycin
(GIBCO Laboratory), and 15% fetal calf serum
(GIBCO laboratory). Incubation was carried out at
37°C in an C02 incubator (the C02 tension was kept
at 5%). The cells were fed twice a week by
replacement of all the medium and when they
reached confluent state (about 2.15xl07 cells in
an 75 ml Falcon culture flask), they would be
trypsinized with 0.25% trypsin plus 1 mM EDTA
(GIBCO Laboratory) at 37°C for 5 min., and
transferred to four new 75 ml Falcon flasks
containing 15 ml culture medium. This would
provide each flask with a cell concentration of
3xl05 cells per ml.
B. Raji
This is one of the first cell lines
established from Burkitt's lymphoma [477]. It is
non-productive and contains about 50 to 60 EBV
genomes per cell [195,328]. The majority of these
viral genomes are carried as free extrachromosomal
DNA plasmids [478,479] but possibly, one or more
integrated copies of the complete EBV genome also
exist [480]. In my experiments, it was used as
positive EBV DNA control.
The culture medium and conditions were
similar to those in NPCHK1 except 10% fetal calf
serum (GIBCO Laboratory) was used instead of 15%.
Moreover, since Raji cells grow in suspending form
(Fig. 7), no trypsinization was needed during the
subculture.
C. 3T3
It is a mouse fibroblastic cell line. The
DNAs extracted from these cells were used as the
negative EBV control.
The medium used was modified Eagle's medium
(GIBCO Laboratory) supplemented with 100 IUml
penicillin plus 100 ugml streptomycin (GIBCO
Laboratory), and 10% fetal calf serum (GIBCO
Laboratory). Other conditions were similar to
those in NPCHK1. Its morphology is demonstrated
in Fig. 8.
Figure 5. Phase contrast micrograph of NPCHK1 cell line.
Figure 6. Phase contrast micrograph of NPCHK1 in a monolayer
outgrowth showing a few round cells on top of the polygonal
cells.
Figure 7. Phase contrast micrograph of the Raji cell line.
Figure 8. Phase constrast micrograph of the 3T3 cell line.
II. Preparation of cord blood lymphocytes
Human cord blood lymphocytes were obtained from
Obstetrics and Gynecology Department of Prince of Wales
Hospital, Hong Kong. They also served as the negative
EBV DNA control.
The method for isolating the lymphocytes from cord
blood was devised by Boyum [481,482]. Equal volume of
heparinized fetal cord blood, Hank's solution (GIBCO
Laboratory), and Ficoll-Hypaque (density= 1.077 gml)
were mixed together and centrifuged at 650g for 30 min.
By using a Pasteur pipette, the lymphocytes
concentrated in the interface were collected. After
washing them two times with serum-free medium, they
were incubated overnight at 37°C. DNA extraction was
then performed subsequently.
Reagents:
1. Ficoll-Hypaque: mixed 9.556 g Ficoll 400
(Pharmacia) and 30ml 50% Hypaque-sodium (Wintrop
Laboratories) in 120.4ml H20, adjusted density to
1.077 gml and millipore filtered.
III. DNA extraction.
A. NPCHK1 and 3T3
a) Cells preparation
Cell monolayer in culture flask was washed
twice with ice-cold Tris-buffer saline. Then
using a rubber policeman, they were scrapped
out into 5ml of the same solution. After being
transferred to a 50ml Falcon conical tube,
cells were collected by centrifugation at 500g
for 10 min. Before DNA extraction, they were
kept in -7 0°C freezer for not less than 16
hours.
b) Cell and nuclear membrane digestion
1 x 10 cells were suspended in 10ml STE with
0.5% SDS and 1 mg proteinase K. Digestion
proceeded at 55°C for 16 hours with constant
shaking.
c) Phenol extraction
10 ml of ice-cold phenolchloroformisoamyl
alcohol (25:24:1) solution was added. The tube
was shaken gently by inversion for 10 min, kept
on freezer for a further 10 min, and
centrifuged at 2000g for 20 min. The
supernatant which contained the nucleic acid
was collected to another Falcon tube by using
the 'mouth end' of a 2 ml glass pipette.
d) Ethanol precipitation
One tenth volume of 3M sodium acetate (pH 5.2)
and two volume of -20°C 95% ethanol were
added. By inverting the tube several times, a
white cloudy aggregate of the precipitated
nucleic acid could be seen. They were spinned
down at 2000g for 20min, resuspended with -20°C
70% ethanol, and centrifuged as previously
done. After decanting the ethanol, the tube
was drained over a paper towel for a few
minutes to remove as much remaining ethanol as
possible.
e) RNA digestion
The pellets were resuspended in 5ml of TE.
After adding 50ul of 10 mgml RNase, it was
incubated at 37°C for 2 hours with shaking. In
order to break down the RNase after the
digestion, SDS and proteinase K were added at a
final concentration of 0.5% and 100 ugml
respectively. The solution was incubated at
55°C for a further one hour and the proteins
were removed by phenol extraction. The DNA
pellets were recovered by alcohol precipi¬
tation.
f) Dialysis and concentration measurement
Being dissolved in TE, the DNA was dialyzed in
the same solvent for 2 days at 4°C. Measuring
the absorbance at wavelength 260, 280, and 330
nm using the Gilford Response UV-VIS
spectrophotometer, the purity and concentration





= 1.8 to 2.0
A2 8 0 A3 3 0
2. DNA concentration
DNA conc.= (A260~ a33o) x SOU?™! x df
(1 unit absorbance at 260nm= 50ugml DNA)
where A260= absorbance at 260 nm
A2o= absorbance at 28 0 nm
A33o= absorbance at 330 nm
DF= dilution factor
Reagents:
1. Tris-buffer saline: containing 137 mM NaCl,
5mM KCl, 25 mM Trizma base (Sigma), and 0.0015%
phenol red; autoclaved.
2. STE: containing 0.1 M NaCl, 0.05 M TrisHCl
pH7.5, and 1 mM EDTA pH7.4; autoclaved.
3. 10% sodium dodecyl sulphate (SDS): dissolved
10 g SDS in 100 ml autoclaved double distilled
water.
4. 10 mgml proteinase K: dissolved 10 mgml
proteinase K (Sigma) in 10 mM TrisHCl pH7.5,
stored frozen at -20°C, thaw when used.
5. Phenolchloroformisoamyl alcohol solution:
make up phenol (Mallinckrodt), chloroform and
isoamyl alcohol (Sigma) with a ratio of 25: 24
: 1 in a tin-foil-wrapped glass bottle. For
100 ml of this mixture, 10 ml 20 mM TrisHCl
pH8.1 was added. After stirring with magnetic
stirrer for 3 hours, it was stored at 4°C until
being used.
6. 95% ethanol: made up with autoclaved H20 and
absolute ethanol, stored at -20°C until being
used.
7. 7 0% ethanol: made up with autoclaved H20 and
absolute ethanol, stored at -20°C until being
used.
8. 10 mgml RNase: dissolved 10 mgml RNase
(Sigma) in 10 mM TrisHCl pH7.5, boiled for 10
min in boiling water bath, and stored at -20°C
until being used.
9. TE solution: containing 0.1 mM EDTA pH7.4 and
ImM TrisHCl pH7.5, autoclaved.
B. Raji and cord blood lymphocytes
Since the cells grew in suspending form, they
were washed directly with Tris-buffer saline for 2
times and subjected to the DNA extraction
procedures mentioned above.
C. Tissue biopsies
Various head and neck tumor tissues were
obtained from different departments of Prince of
Wales Hospital. Normally, their weight ranged
from 0.02 to 0.4 g. The histologic diagnosis and
the corresponding codes used by me were depicted
in table 5.
For DNA extraction, various tissues must
firstly be minced to small fragments so as to
facilitate the proteinase K digestion. The whole
extraction procedures were essentially similar to
that in section A.
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Figure 9. Undifferentiated carcinoma of the parotid gland-
malignant lymphoepithelial lesion. The epithelial tumour mass,
with vesicular nuclei, is surrounded by lymphocytic infiltration
(II E, X250).
Figure 10. Benign thymoma in a patient with myasthenia gravis
(S —3 4 0 2). The tumour cells contain vesicular nuclei and
indistinct cell border and scanty lymphocytic infiltration is
present.
Figure 11. Benign thymoma in a patient without myasthenia
gravis (KH87-1277). The nuclei of the tumour cells are spindle-
shaped and vesicular. Their cell borders are indistinct. Only
scanty lymphocytic infiltration can be seen.
Figure 12. Myasthenia thymic hyperplasia (S-9838). A large
germinal centre is located at the centre, with acivated
lymphocytes surrounded by the small lymphocytes with dark-
stainning nuclei. A Hassell's corpuscle is located next to the
germinal centre (arrow).
Figure 13. Myasthenia thymic hyperplasia (S-3245). The number
of germinal centre is less than the sample of S-9838. One of
them is shown near the centre. Perivascular space (thick arrow)
and Hassell's corpuscle (thin arrow) can also be seen.
IV. Preparation of radioactive probe
A. Nick-translation
The EBV-DNA used was the BamHI-W repeat of
B95-8 cloned in pBR322 plasmid. It was kindly
provided by Dr. Paul Farrell, Ludwig Institute for
Cancer Research, Cambridge, England and was
labeled radioactively with (32P)dCTP (Amersham) by
using the Amersham N5000 nick-translation kit.
Typically, 0.4- 0.8ug BamHI-W repeats was
incubated with 125 uCi (32P)dCTP, 20ul solution 1
and lOul solution 2. The reaction volume was
added up to lOOul with distilled water.
Incubation was carried out at 15°C for two hours.
After adding 20 ul 0. 5M EDTA (pH8.0), 1.5ul 1%
bromophenol blue and 80ul solution 3 (carrier
DNA), the mixture was loaded onto a Sephadex G-50
column (Pharmacia). This will separate the long
usable labeled fragments and normally 40 tubes of
the elution were collected with 3 drops per tube.
For finding out which tubes contained the
labeled probe, 1 ul of the elution from each tube
was mixed with 1 ml Beckman Read-Solvx. multi¬
purpose liguid scintillant cocktail. Liquid
scintillation counting was carried out in a
Beckman LS9800 liquid scintillation counter.
Normally, three tubes would contain the highest
count and they would be pooled together. The
specific activity was determined by trichloroace¬
tic acid precipitation.
Reagents:
1. Amersham N5000 nick-translation kit:
a) Solution 1: containing 100 uM dATP, 100 uM
dGTP, and 100 uM dTTP in TrisHCl, pH7.8,
magnesium chloride, and 2-mercaptoethanol.
b) Solution 2: containing 2 units DNA
polymerase I and 100 pg DNase I in lOul
TrisHCl, pH7.5, magnesium chloride,
glycerol, and bovine serum albumin.
c) Solution 3: 2.5ml carrier DNA solution.
d) Solution 4: 5ug25ul lambda DNA restriction
fragments in dilute buffer solution
containing TrisHCl, pH8.0, and EDTA.
2. Gel swellingrunning buffer: containing 100 mM
TrisHCl, pH7.5 and 50 mM MgCl2•
3. Sephadex G-50 column: dry Sephadex G-50
(Pharmacia) was swelled in gel swelling buffer
for at least 18 hours at room temperature. It
was then poured into a Bio-rad Econo-column
chromatography column, washed several times
with buffer, and allowed to stabilize until
being used.
B. Probe specific activity determination- Trichloroacetic
acid (TCA) precipitation
lul of the sample was diluted in 200ul 0.2 M
EDTA, pH8.0. After setting aside lOOul for the
determination of total input radioactivity, the
remaining was mixed with 50ul carrier DNA
(solution 3 of the Amersham N5000 nick-translation
kit). 2ml ice-cold 10% trichloroacetic acid was
then added and the mixture was allowed to stand in
ice bath for 15 min. The precipitated DNA was
collected on a nitrocellulose filter disc
(Schleicher Schuell). After a further washing
with 2ml 10% TCA solution, the filter was dried
thoroughly under a lamp. The radioactivity was
determined by immersing the disc into 2ml Beckman
scintillation cocktail and counted in the liquid
scintillation counter.
For determinating the total input of
radioactivity, lul sample was taken out from the
lOOul mixture and counted directly with the
scintillation cocktail. The percentage of
incorporation and specific activity of the probe







wt. of probe used for labeling (ug)
where V= volume of the probe solution
Reagents:
1. 10% ice-cold trichloroacetic acid (TCA): 50g TCA
was dissolved in 227ml autoclaved H20; stored at
4°C.
V. Dot blot filter preparation
A. Set up of dot blot manifold
For easy sample application, dot blot filter
was prepared by using a Bio-rad microfiltration
apparatus. The assembly of the apparatus is
demonstrated in Fig. 14. A nitrocellulose filter
was wetted in autoclaved distilled water for 20
min and immersed in 20xSSC solution for a further
20 min. It was then clamped between the 96 wells
gasket and 96 wells sample template, aligned above
the support plate, and situated over the vacuum
manifold. After holding the assembly tightly with
the four screws, vacuum was applied and the
tightening process was repeated so as to assure







. tubing and flow vaivc
3L4• Assembly of the BiODot inicrof iltrat-.on
apparatus (Bio-rad)•
B. Sample application
Aliquots containing l-10ug DNA was denatured
by boiling for 5 min in water bath and chilled
immediately in ice. After washing each of the
wells with lOOul 20xSSC, samples were applied to
the pre-selected wells. The excess solution could
be drained by vacuum. After washing the wells
with 1M ammonium acetate, the filter was allowed
to dry under a lamp and baked at 80°C for 2 hours.
Before hybridization, the filter was stored in a
desiccator.
VI. Southern blot filter preparation
A. Restriction enzyme digestion
Typically, in an Eppendorf centrifuge tube,
lOug of sample DNA was mixed with 2 0 units BamHI
enzyme and 4ul lOx enzyme buffer. After the
reaction volume had been adjusted to 2 0ul with
H20, incubation was carried out in a 37°C water
bath for 16 hours. The reaction was stopped by
addition of 0.8ul 0.5 M EDTA, pH8.0.
Reaaents:
1. lOx enzyme buffer: containing 100 mM TrisHCl,
pH8. 0, 1 M NaCl, 100 mM MgCl2, lOmM beta-
mercaptoethanol (Sigma) and 1 mg bovine serum
albumin (Sigma).
B. Agarose gel electrophoresis
Digested DNA samples were heated to 65°C for
5 min, placed on ice for 10 min, and mixed with
4ul 6x gel loading buffer. Using TBE as the
running buffer, the DNAs including the size marker
were electrophoresed through 0.8% agarose gel
horizontally for 8 hours at 80 voltages. After
the running, DNA was stained by in TBE containing
0.5 ugml ethidium bromide (Sigma) for 25 min at
room temperature. Destaining was not required and
the electrophoretic pattern was recorded by
photographing the gel under a Polaroid MP-4 land
camera using the Polaroid 667 film (ASA 3000).
The UV source was generated by Transilluminator
TS-36 (Ultra-violet Products, Inc.).
Reagents:
1. 6 x gel loading buffer: containing 0.25%
bromophenol blue, 0.25% xylene cyanol (Sigma),
and 30% glycerol in H20. The solution was
stored at 4°C until being used.
2. Tris-borate buffer (TBE): containing 0.5 M
Trizma base (Sigma), 0.5 M boric acid (BDH),
and 0.025 M EDTA (Sigma). The pH was adjusted
to 8.0 and autoclaved.
3. Size marker: lug lambda DNAHind III fragments
in TE (Pharmacia).
4. 0.8% agarose gel: Dissolving 0.8g agarose gel
powder (Pharmacia) in 100 ml TBE using a
microwave oven. After allowing it to cool to
about 50°C, it was poured into the gel tray.
C. Southern transfer
After transferring the gel to a glass baking
dish, DNA denaturation was done by soaking the gel
in denaturing buffer for two times, each lasts for
15 min, followed by dipping into neutralizing
buffer for two times, each also lasts for 15 min.
The set up of the transfer system was essentially
similar to that proposed by Maniatis et al [483]:
A plastic support was placed inside a large
tray containing 2 0xSSC. One long Whatman 3 MM
paper prewetted with neutralizing buffer was laid
on it so that its two ends extended into the
2 OxSSC. After inverting the gel with with its
original underside became uppermost, it was placed
on the damp 3MM paper. A nitrocellulose filter
(BRL) prewetted with H20 and 20xSSC was then
overlaid the gel. Three additional neutralizing
buffer-prewetted 3MM paper were placed on its
surface. A stack of dry paper towels, one plastic
plate, and a 500 g weight was exerted to the
assembly (Fig. 15). Transfer was allowed to
proceed for 18 hours. The resultant nitrocellu¬
lose filter was incubated in an oven at 80°C for
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VII. DNA hybrid ization
A. Dot blot filter
a) Prehybridization: Firstly, nitrocellulose
filter was wetted thoroughly with prehybridiza¬
tion solution. Then, it was placed inside a
heat sealable plastic bag. After adding 50-
lOOulcm prehybridization solution, the open
end of the plastic bag was sealed with a heat
sealer. Incubation was carried out by submer¬
ging the bag into a 42°C water bath for 6
hours.
b) Hybridization: After squeezing out the
prehybridization solution by clipping off a
corner in the plastic bag, 50- 100 ulcm
hybridization solution was added. The opened
corner was resealed and the bag was submerged
in a 4 2 °C water bath for 16 hours. The
stringency washing was carried out according to
table 6.
c) Autoradiography: The washed filter was wrapped
in Saran Wrap. It was placed inside a x-ray
film cassette box and taped. In the dark room,
an Amersham Hyperfilm autoradiography film was
laid on the filter. Exposure was allowed to
proceed at -70°C for 24- 48 hours.
B. Southern blot filter
The procedures for prehybridization and
hybridization were similar to those used in dot
blot filter except the conditions for
stringency washing was different. They were
summarized in table 6, too.
Reagents:
1. 2 OxSSPE: containing 3 M NaCl, 0.2 M
NaHPO.EO, 2 0 mM EDTA; pH was adjusted to 7.4
with NaOH.
2. 100% Deionized formamide: mixed 100 ml
formamide (Sigma) with 4 g Amberlite MB-1
(Sigma) in a tin-foil wrapped glass bottle.
After stirring for one and a half hours, the
formamide was filtered through a Whatman No.l
paper for two times.
3. Prehybridization solution: containing 50%
deionized formamide (Sigma), 5xSSPE, 0.1%
bovine serum albumin (Sigma), 0.1% Ficoll-400
(Pharmacia), 0.1% polyvinylpyrollidone (Sigma),
0.5% SDS, and 200ugml sonicated salmon sperm
DNA (Sigma).
4. Hybridization solution: containing prehybridi-
zation solution plus lOOpg nick-translated DNA
probe with a radioactivity of more than 1x10
cpm.
TABLE 6. STRINGENCY WASHING CONDITIONS FOR DOT BLOT
AND SOUTHERN BLOT FILTER
DOT BLOT FILTER
WASH IN G SOLUTI 0 N TEMPERATURE
(°C)
DURATION
( M I N)
WASH ING TIMES
2 x S S C
2 x S S C 0.1% SDS
1x S S C 0.1% SDS
0. 5 x S S C 0.1% SDS





















WASH ING SOLUTION TEMPERATURE
( °C)
DURATION
( M I N)
WASH ING TIMES
2 x S S C
2 x S S C 0.1% SDS
1x S S C 0.1% SDS



















Totally 20 tissue culture and 19 tissue biopsy
samples were extracted for DNA. Using my method, the
average 260280 ratio was 1.853 with a sample standard
deviation of 0.033. Fig. 16 shows a typical curve
plotted against the absorbance and the corresponding
wavelength for scanning. Normally, a minimum 0.015g
tumor biopsy tissue is needed for each DNA extraction.
II. Nick-translatson
As a whole, thirteen times of nick-translation
have been done. Fig. 17 shows a typical curve for the
distribution of radioactivity in different Sephadex G-
50 elution fractions. Normally, the fraction 6 to 10
contained the 32P labeled EBV probe. The optimal
amount of the BamHI-W used for labeling was 330ng, with
a resulting specific activity of 2-3xl08 cpmug. The
counting efficiency for the liquid scintillation
counting has been determined to be 94%. However, in
the later experiments, automatic quenching compensation
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Figure 16. Diagram of a typical spectropho¬
tometry scanning pattern of extracted DNA sample.
A single peak A is seen at about 260 nm. Its
height represents the concentration of DNA, namely
1 absorbance equals to 50 ugml. The slope in the
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Figure 17. Distribution of radioactivity in
Sephadex G-50 elution fractions in the nick-
translation experiment. The radioactivity is
measured by mixing 1 ul of the eluted sample with
1 ml counting cocktail and counted in a Beckman
LS-9800 liquid scintillatioin counter. The first
peak represents the radioactivity incorporated
into the probe while the second one is due to the
existence of free unincorporated P.
III. Agarose gel electrophoresis
Fig. 18 shows a UV-photograph of the gel aftei
ethidium bromine staining.
IV. Optimal stringency washing condition
I have tried to wash the hybridized filters with
different combinations of temperature, washing duration
and SSC concentration. The tested conditions and their
outcomes are summarized in table 7. The optimal
washing conditions in terms of sensitivity are listed
in table 6.
V. Sensitivity of DNA hybridization
The experimental system of the Southern blot
hybridization method using the BamHI-W probe in our
laboratory could routinely detect lOOpg pure BamHI-W
fragment and those W-repeats in 0.01 ug of Raj i cell
DNA. Taking 5ug of cellular DNA is eguivalent to DNA
amount present in 106 cells [424], the experimental
system could regularly detect 2000 Raji cells. Since
each Raji cell contains about 50 EBV genomes [195,328],
the sensitivity of detection is 105 genomes. Thus for
lOug of DNA sample, the Southern blot hybridization has
a sensitivity of 0.05 EBV genomes per cell.
123456789 10 11 12 13
figure 18. A typical UV-photograph of a gal after elec¬
trophoresis.
Lane 1: lOug Raji DNA
Lane 2: 5ug Raji DNA
Lane 3: lug Raji DNA
Lane 4: lOug normal nasopharyngeal mucosal DNA (NPl)
Lane 5: lOug normal nasopharyngeal mucosal DNA (NP2)
Lane 6: lOug normal nasopharyngeal mucosal DNA. NP3)
Lane 7: lOug normal nasopharyngeal mucosal DNA (NP4)
Lane 8: lOug NPCHKl DNA
Lane 9: lOug undifferentiated NPC DNA
Lane 10; lOug cord blood lymphocyte DNA
Lane 11: lOug 3T3 DNA
Lane 12; lOug Raji DNA
Lane 13: lug lambda DNA marker
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VI. Dot blot hybridization
A, NPCHKl cell line and normal nasopharyngeal
biopsies
Fig. 19 shows the result of dot-blot DNA
hybridization on the well differentiated NPC cell
line, NPCHKl, and four different normal
nasopharyngeal mucosa tissues. Column 1, which
represents the Raji cell DNA, having DNA amount as
10 ug, 5ug, and 1 ug respectively from the top to
the bottom, showing the strong positive signal.
In contrast, the NPCHK1 (column 2) and the four
nasopharyngeal tissues (column 3-6) were
negative. Thus both the NPCHK1 cell line and the
normal nasopharyngeal mucosa lacked detectable EBV
genome.
B. Salivary gland tumors and carcinoma of tongue
Fig. 20 shows the dot blot hybridization
result of different salivary gland tumors and a
sample from patient with carcinoma of tongue.
Positive signal can be seen in the
undifferentiated carcinoma of the parotid gland
(column 3) which has histological features similar
to undifferentiated type NPC (WHO 3) (Fig. 16,
17). In another type of parotid gland tumor, the
adenocarcinoma (column 1 and 2), no EBV DNA can be
detected. The negative signal can also be seen in
the squamous cell carcinoma of the base of tongue
(column 4).
C. Different kinds of thymus tissue
Fig. 21 shows the result of nucleic acid dot
hybridization of different thymus tissues.
Positive EBV DNA signal is found in patient with
malignant thymoma and myasthenia gravis (column
2), with malignant thymoma only (column 3) and
with myasthenic thymic hyperplasia (column 4 and
5). No EBV genome can be detected in normal
thymus tissues (column 6 and 7). The positive
signal in patient with thymoma and myasthenia
gravis is comparable to the positive control, the
Raji cell (column 1). Comparatively weaker signal
is seen in one of the myasthenic hyperplasia, the
S-3245 (column 5).
Figure 19. Detection of EBV-DNA from NPCHX1 and naso¬
pharyngeal mucosa tissue. Extracted DNA were immobilized
on nitrocellulose filter and hybridized with 32P-labelled
E3V BamHI-W probe.
Column 1 J EBV positive lymphoblastoid cell line Rajj
Column 2: Well differentiated NPC cell line, NPCHX1
Column 3: Normal nasopharyngeal mucosa (NPl)
Column 4: Normal nasopharyngeal mucosa (NP2)
Column 5: Normal nasopharyngeal mucosa (NP3)
Column 6: Normal nasopharyngeal mucosa (NP4)
Row 1: 10 ug DNA sample
Row 2: 5 ug DNA sample
Row 3: 1 ug DNA sample
1 2 3 4 5 6
Figure 20, Detection of ESV-DNA from different head and
nack tumour tissues with 2P-labollod E3V BamHI-W probe.
Column 1: Adenocarcinoma of the parotid aland (172-T)
Column 2; Parotid gland adenocarcinoma metastasized to
lvmoh node (172-LN)
Column 3: Undifferentiated carcinoma of the parotid
aland (13(5)
Column 4; Squamous coll carcinoma of the base of tongue
(114)
Column 5: Human cord blood lymphocyte (CBL)
Column 6: EBV positivo lymphoblastoid cell line, Haji
How l: 10 ug DNA samplo
How 2: 5 ug DNA sample
How 3; 1 ug DNA samplo
1 2 3 4 5 6 7 8
Figure 21. Nucloic acid dot hybridization against EBV
BamHI-W on different thymus tissue.
C 0lum n 1; P T3 V rin cri M vr n 1 vmnhnhl anfni rfll T H nfl. ft 4 f
Column 2: Pationt with thymoma and myasthenia gravis
(8-3402)
Column 2 i ?ak(enk vifch thvmoma onlv (X_HQ7-1277)
Column 4: Patient with myasthenic thymic hyperplasia
(8-9038}
Column 5: Patient with myasthenic thymic hyperplasia
Column 6: Normal thymus (8-3646)
Column 7: Normal thymus (S-1963)
Column 0: Human cord blood lymphocyte (CJ3L)
Row 1: 10 ug DNA sample
Row 2: 5 ug DHA sample
Row 3: 1 ug DNA sample
VII. Southern blot hybridization
A. NPCHK1, WHO 3 NPC and normal nasopharyngeal
tissues
Fig. 22 shows an autoradiogram of the
Southern blot hybridization result of NPCHK1,
undifferentiated NPC (WHO 3) and four normal
nasopharyngeal tissues. Positive signal can be
obtained in the undifferentiated NPC (lane 7) and
Raj i (lane 1 and 2). In the undifferentiated NPC
tissue (lane 7), a band lies at 3 kilobase site
similar to that in Ra j i cell DNA. In NPCHK1
(lane 8) and the four nasopharyngeal tissues (lane
3- 6), no detectable EBV genome can be found.
B. Different head and neck tumors
In Fig. 23, it demonstrates that in addition
to Ra j i cell (Lane 1, 2, 3, and 11), both
undifferentiated carcinoma of the parotid gland
(lane 4) and the submandibular lymph node with
metastasized undifferentiated carcinoma (lane 7)
contain detectable EBV DNA. The size of these
fragments lie at about 3 kilobase and the
intensity of the positive signal is between 1 to 5
ug Raj i DNA. In parotid gland adenocarcinoma
(lane 5), its metastasis in lymph node (lane 6),
carcinoma of the tongue (lane 8), and the human
cord blood lymphocyte (lane 10), no detectable EBV
genome can be found.
C. Different thymus tissues
Fig. 24 shows the autoradiogram of the
Southern blot hybridization result in different
thymus tissues. Positive EBV signal can be found
in patient with malignant thymoma and myasthenia
gravis (lane 3), with malignant thymoma only (lane
4), and with myasthenic thymic hyperplasia (lane 5
and 6). The bands all lie near the 3 kilobase
site. In the two thymoma samples (lane 3 and 4),
the intensity of positive EBV signal is more than
that with 5 ug Ra j i DNA. In the thymoma with
myasthenia gravis (lane 3), the signal even
comparable to 10 ug Raji DNA. However, in the two
myasthenic thymic hyperplasia samples (lane 5 and
6), the EBV genome equivalent are less than that
in 5 ug Raj i DNA. In normal thymus tissues and
3T3 cell, no detectable EBV DNA can be seen.
Figure 22. Autoradiogram of a Southern blot showing
detection of EBV DNA in NPCHX1, undifferentiated NPC,
and normal nasopharyngeal tissues.
Lane l; 10 ug Kaji DNA
Lane 2: 1 ug Raji DNA
Lane 3: 10 ug normal nasopharyngeal tissue (NPl)
Lane 4: 10 ug normal nasopharyngeal tissue (NP2)
Lane 5: 10 ug normal nasopharyngeal tissue (N?3)
Lane 6: 10 ug normal nasopharyngeal tissue (NP4)
Lane 7: 10 ug DNA from a undifferentiated NPC (WHO 3
Lane 8: 10 ug DNA from NPCHX1
1 2 3 4 5 6 7 8 9 lO u
figure 23. Autoradiogram of a Southern blot shoving
detection of EBV DNA in different head and nac)c tissues.
Lane 1: lo ug Raji DNA
Lane 2: 5 ug Raji DNA
Lane 3: l ug Raji DNA
Lane 4: 10 ug DNA from an undifferentiated carcinoma of
the parotid gland (13)
Lane 5: 10 ug DNA from an adenocarcinoma of the parotid
gland (172-T)
Lane 6: 10 ug DNA from lymph node with metastasized
parotid gland adenocarcinoma cell (172-LN)
Lane 7: Submandibular lymph node with undifferentiated
carcinoma (163-LN)
Lane 8: 10 ug DNA from carcinoma of the tongue (114)
Lane 9: 1 ug Hind III digested lambda DNA
Lane 10: 10 ug DNA from human cord blood lymphocyte
Lane 11: 10 ug Raji DNA
1 2 34 5 6789 10 11
3kb
Figure 24. Autoradiogram of a Southern blot showing
detection of E3V DNA in different thymus tissues.
Lane 1: 10 ug Raji DNA
Lane 2: 5 ug Raji DNA
Lane 3: 10 ug DNA from patient with thymoma and myas¬
thenia gravis (3-3402)
Lane 4: 10 ug DNA from patient with thymoma only (KH37-
1977)
Lane 5: 10 ug DNA from patient with myasthenic thymic
hyperplasia (S-9838)
Lane 6: 10 ug DNA from patient with myasthenic thymic
hyperplasia (3-3245)
Lane 7: 10 ug DNA from normal thymus (3-3546)
Lane 8: 10 ug DNA from normal thymus (3-1963)
Lane 9: 1 ug Hind III digested lambda DNA
Lane 10: 10 ug 3T3 DNA
Lane 11: 10 ug Raji DNA
DISCUSSION
I. Methods
In the DNA extraction procedure, normally 0.015ug
tissue DNA was sufficient. This requirement met the
limit for most of the tumor tissues. However, during
the resuspension step after the second time of alcohol
precipitation (after RNase treatment), volume of the
added TE should be controlled so as not to let the DNA
samples to be diluted too much. The judgment should be
guided by experience.
In the nick-translation reaction, the reaction
mixture was incubated at 15°C. This temperature is
very critical to avoid the generation of 'snap-back7
regions in the labeled DNA. It has been suggested that
this temperature should be achieved by using a cooling
coil or circulating cooler with a conventional
thermostatically controlled water bath. However, in my
experience, a surprisingly good temperature control
could be achieved by adding ice to a polystyrene foam
container with suitable amount of water.
In the hybridization experiment, normally the
probe containing a total of lxlO7 cpm radioactivity was
sufficient to give satisfactory signal. However, this
is true only if the amount of DNA probe exceeded 50 ng.
In fact, the amount of DNA probe used is critical to
achieve the satisfactory signal, too. It shall be safe
to use 100 ng probe for each hybridization experiment.
Another important factor which governs the signal to
noise ratio is the stringency washing condition. As
indicated in table 6, I have spent lots of time to find
out the optimal conditions for filter washing. It was
found that washing the filter with 0.lxSSCO.1%SDS at
high temperature (higher than 50°C) could significantly
decrease the sensitivity. In order to increase the
sensitivity, the stringency washing conditions must be
monitored. Since stringency can be decreased (thus
increase the sensitivity) by either increasing the salt
concentration or decreasing the washing temperature,
optimal conditions were developed according to this
trend. By using the conditions listed in table 7, I
could detect 0.05 EBV BamHI-W DNA in each testing cell.
This finding is comparable to what have been reported
by Andiman and his co-workers [424]. Moreover, it is
obvious that higher stringency washing is reguired in
dot blot filter than in Southern blot filter to remove
non-specific binding. This can be explained by the
phenomenon that DNA sample in dot blot filter are more
closely packed. The 'net-working' effect can increase
the non-specific tracking of the probe. They must be
removed by washing under a more stringent condition.
Finally, although the probe used contained pBR322
vector, it is unlikely that the hybridization signal
came from it rather than from the BamHI— W fragment
because in Southern blot experiment, only one band with
3kb size was observed.
I!. Lack of EBV DNA in NPCHK1
In 1983, Raab-Traub and associates first reported
EBV RNA expression in a well differentiated NPC (WHO 1)
biopsy. The transcriptional patterns represented state
of abortive infection not stimulated by any of the in
vitro systems [334] such as that in lUdR-induced Raj i
cells [484]. It was after cloning the NPC DNA into a
cosmid vector that EcoRI B, C, DIJhet, E, F, Gl, G2 and
J fragments could be recovered by Southern method
[337]. More recently, 5 more WH01 NPC biopsies were
reported to contain BamHI-W fragments, although at very
low copy number [337]. Nevertheless, since there is
always lymphocytic infiltration in the biopsy tissue,
the EBV may come from the non-tumorous lymphocytes.
Moreover, WH01 NPC tumor may contain small foci of
undifferentiated cells [322]. One can still argue that
the much lower copy number of EBV genome come from
them. The question may be answered by performing in
situ hybridization or using a suitable cell line.
Up to now, three well differentiated NPC cell
lines have been established including the NPCHK1.
Common characteristics can be noticed between them:
1. they are xenotransplantable;
2. no viral particles can be revealed under electron
microscope before or after lUdR treatment; and
3. no EA can be detected after lUdR induction.
In NPCHK1, no BamHI-W could be detected.
However, one cannot exclude the possibility that low
number of EBV genome has been diluted out during the
continuous passages. Nevertheless, NPCHK1 is similar
to those previously established WHO 1 NPC cell line
that no EBNA could be detected in the cells from the
primary culture and several of the subcultures. It
seems that my finding is a truly negative one.
On the other hand, in my experiment I was only
probing against the BamHI-W fragment. A particular
advantage of probing this fragment is that it is highly
reiterated in the EBV genome so that it provides a
sensitive target for detection. Moreover, this
fragment is also essential for the immortalization
capacity of the virus [222,223]. According to my
literature review, all EBV strains exist in the
epithelial tumors carry the BamHI-W [304,327,331,333,
442]. The five EBV DNA-positive WHOl NPC biopsies also
contained it [337]. So it is unlikely that the NPCHK1
lacks BamHI-W but contains other EBV DNA fragments.
Recentlv, an epithelial cell line has been
established from a human embryo nasopharynx in China
[485]. It has the characteristics of carrying typical
epithelial morphology under light microscope and
electron microscope, no adhesion with B95-8 and Raji
cells, and contained no VCA and EBNA.
Xenotransplantation of 2 x 1070.2 ml cells into nude
mice produced a tumor mass after two weeks and
histologic studies confirmed it as squamous cell
carcinoma. Since no transformation inductants had been
added during the culture experiment, the sguamous cell
carcinoma arouse from the transplanted non-neoplastic
cells. The significance of this finding is that it
demonstrates transformation of the normal
nasopharyngeal cells into tumor, at least in the
athymic nude mice system.
It is possible that similar to Burkitt's lymphoma,
WHO 1 NPC also exists in two forms. One shows
association with EBV and the other does not. For
unknown reason, only the latter type which is devoid of
EBV can grow into cell line. Nevertheless, it is still
possible that the EBV-carrying tumor cells have been
lyzed and diluted out during the passages. Under this
circumstances, only the EBV negative tumor cells form
the cell line. Clearly, more cell lines must be
established to clarify this point.
III. Lack of EBV DNA in normal nasopharyngeal
biopsies
Tugwood and associates reported that normal
nasopharyngeal tissues had EBV DNA transcription [335].
In their experiment, frozen tissues were disrupted in a
Mikro-dismembrator and cytoplasmic RNA and DNA were
simultaneously prepared. Total cytoplasmic RNA was
then degraded with alkali and end-labeled with
[32pjatp. They were hybridized to Southern blots of
cloned EBV DNA fragments. Autoradiogram showed that
EBV DNA seguences which are expressed during latent
lymphocyte infection (BamHI-w, -Y, -H, -K, and EcoRI-J)
were transcribed in normal nasopharyngeal tissues, too.
Occasionally, some samples even expressed EcoRI-E which
is believed to encode a VCA protein (probably the 150
kb major capsid protein). Unfortunately, EBV genome
could not be detected in our four nasopharyngeal mucosa
tissues. Similarly, negative result also obtained from
other studies [327,337]. This discrepancy may due to
the following reasons:
1. In Tugwood and associates studies, the mixture of
total cytoplasmic mRNAs were used as probe. It has
been claimed that RNA probes have higher sensitivity
over double-stranded DNA probe [486];
2. the RNA-DNA duplexes formed are more stable than
DNA-DNA duplexes [487];
3. Amplification of the target sequences has occurred
during transcription so that it is easier to detect
such large amount of RNA than detecting the scanty
EBV DNA in the nasopharyngeal cells.
It was reported by Desgranges and associates [333]
that among 46 Chinese nasopharyngeal cells (20 IgAVCA-
positive and 26 IgAVCA-negative) tested in 1981, 7 of
them were found to contain EBV DNA (5 from IgAVCA-
positive group and 2 from IgAVCA-negative group).
After one year, only 3 of them still maintained the
detectability (2 of them from the 5 IgAVCA-positive
and EBV DNA positive individuals and the other one came
from the two IgAVCA-negative but EBV DNA positive
persons). These variations observed in the
detectability of EBV DNA after a year might reflect a
fluctuation of the EBV activity in the nasopharyngeal
mucosa.
Based on the result that structural viral antigens
and EBV DNA could only be detected in desquamated
oropharyngeal cells [470,488], Sixbey and associates
suggested that the oropharyngeal epithelial cells, once
infected, became permissive to viral replication only
on reaching a certain phase of cell maturation. Since
oropharyngeal cells are anatomically close to and
morphologically similar to nasopharyngeal cells, it is
possible that this phenomenon is also true in the
nasopharyngeal cells. In fact, by using monoclonal
antibodies HB5 and anti-B2 [489,490], EBV receptors
could be identified in both the nasopharyngeal cells
and the oropharyngeal cells in a cell differentiation-
dependent manner, namely with the basilar cells showing
the strongest fluorescence [119]. In this context the
infection of receptor positive basal epithelium,
followed by virus replication in progeny cells as they
approach terminal differentiation [470], could provide
a self-sustaining reservoir of the infection in the
pharynx.
Based on these findings, it is possible that since
the cells which have reached that particular stage of
maturation are more scanty in the nasopharynx than the
oropharynx, only limited EBV are produced. They can
only be detected by either using a more sensitive
method or when the time has reached that more cells
mature synchronously to the stage to produce EBV. It
is the latter speculation that let me to interpret
Desgranges and associates findings [333].
IV. EBV DNA in Submandibular lymph node with
lymphoepifchehoma-Iike metastasis
Among the EBV positive samples, one of them comes
from a patient with metastatic lymphoepithelioma-like
lesion in the submandibular lymph node. In these lymph
nodes, they were invaded by sheets of undifferentiated
carcinoma cells. These cells had round to oval
vesicular nuclei and prominent pinkish nucleoli and
eosinophilic cytoplasm. Lymphocyte infiltration was
seen and the syncytial sheets of tumor cells partially
replaced the lymph node architecture. Thus the
histological appearance is similar to undifferentiated
NPC (WHO 3). However, repeated nasopharyngeal biopsies
only showed chronic inflammation. Using DNA
hybridization techniques, I confirmed that it contained
EBV DNA. Thus summing up the clinical, histological
and hybridization data, a nasopharyngeal primary could
be strongly suggested. As many NPC patients who have
lymph node metastasis in the neck region can lack a
notable tumor in the nasopharynx. Thus, combining the
information from clinical features, histology and
hybridization studies can assist in the NPC diagnosis
and facilitates the selection of suitable therapy.
V. Lack of EBV DNA in carcinoma of the base of
tongue
Lanier and associates [327] reported EBV DNA was
absent from a patient with squamous papilloma of
tongue. My negative finding in moderately differen
tiated carcinoma of base of tongue shows that EBV has
no association with this type of tongue tumor.
VI. EBV DNA in undifferentiated carcinoma of
the parotid gland
Primary salivary gland tumors are rare. It
comprises less than 3% of all neoplasms in the head and
neck region. The great majority of them are located in
the parotid gland, followed by the minor salivary
gland, submandibular gland, and sublingual gland in
descending order [491]. According to the World Health
Organization, these tumors can be classified into
epithelial tumors, non-epithelial tumors, unclassified
tumors and allied conditions [492] (see appendix I).
Among them, the undifferentiated carcinomas comprising
4.5% [493]. By definition, they are the malignant
epithelial tumors that consist of very poorly
differentiated cells. Among them, a subgroup called
malignant lymphoepithelial lesion (MLEL) can be
identified. It is characterized by containing extensive
and heavy lymphocytic infiltration. Histologically, it
is similar to WHO 3 NPC. Although this lesion can be
found in other populations [494,495,496], highest
incidence is found in Greenland Eskimos [437,497] so
that it is also called Eskimo cancer.
In my experiment, the undifferentiated parotid
gland carcinoma sample belongs to this subtype (Fig.
9). My literature review showed that this is the first
case occurring in Hong Kong Chinese where serological
profile as well as DNA analysis were consistently
supporting sn association with EBV. The oth©r fiv©
cases reported previously were all of Eskimo origins
[281,327,437,498]. Although by in situ hybridization
Wolf and associates have detected EBV DNA in three
normal parotid gland samples [476], Fox and associates
have failed to detect EA-D and EBV DNA by monoclonal
antibodies and Southern blot hybridization method
respectively in 10 normal salivary gland biopsies
[499]. These discrepancy may indicate that only small
amount of epithelial cells in the parotid gland support
viral replication. By in situ hybridization, one can
detect specific nucleic acid sequence in a few cells
against a broad innocent background. It can counteract
the 'dilution effect' of cellular DNA inherent in the
total DNA extraction procedure and highlights those
scanty EBV-positive cells. However, in my case a true
EBV association with the tumor could be supported by:
1. serum IgAVCA and IgAEA were raised to 32 0 and 8 0
respectively, similar to that in WHO 3 NPC [500].
2. EBV DNA could not be demonstrated in another
adenocarcinoma sample which might also carrying
normal parotid gland tissues; and
3. anti-complement immunofluorescence test had found
that EBNA existed in the nuclei of the tumor cells
[500].
Thus based on our findings, the association
between EBV and MLEL should no longer be restricted to
Eskimos, but extended to include Chinese, too. Since
MLEL is similar to the undifferentiated NPC (another
EBV-related carcinoma which has high incidence in both
Eskimos and Southern Chinese) in both histology and EBV
DNA detectability, it is possible that the two tumors
share a common etiological agent in oncogenesis such as
EBV. Both MLEL and NPC occurs frequently in Eskimos.
But in Chinese, only NPC has high incidence. This
discrepancy indicate that other genetic and
environmental factors may contribute to the etiology of
MLEL. In fact, familial clustering of MLEL has been
reported in two Eskimo families [501] and one Finnish
family [502]. In 1970, Rowe and associates had studied
the possible carcinogenic effects of nutritional,
thermal, and endocrine factors on chemically induced
salivary gland tumors in rats. Their data demonstrated
that only those with vitamin A deficiency showed an
increased incidence [503]. Although the deficiency has
been reported in Alaskan Natives, it cannot be proved
in the patient reported so far [504].
Since consumption of Cantonese-style salted fish
has been suggested as a risk ractor for NPC development
[94], it is possible that the prevalence of MLEL in
Eskimos is also related to food habits. In fact,
Poirier and associates have found that N-
nitrosodimethy1amine (NDMA) varied from 8.6 to 38.0
ugkg existed in the dried and unsalted fish which are
consumed daily by Greenland people [104] (most Western
preserved or fresh fish products and other food contain
less than 1 ugkg of NDMA [505]). Although similar
levels of NDMA was found in the salted fish consumed in
Japan [506] where salivary gland tumor are rare, it is
still possible that other additional non-volatile,
unidentified nitrosamines or other carcinogens or co-
factors do exist in the Greenland salted fish.
Alternatively, since carcinogenesis is a multistep
process, one can suspect that the combination of
sequential carcinogenesis events is not identical in
Japanese and in Greenland Eskimos and between NPC and
MLEL. Clearly, no further insight can be obtained only
if the detailed analysis of these food items have been
completed.
VII. EBV DNA In different thymus tissues
Thymoma is a neoplasm arising from the thymic
epithelial cells exhibiting heterogeneous morphology.
It is associated with a variable number of lymphocytes
[507,508,509,510,511,512,513]. They are T cells which
have a phenotype similar to those in the normal thymic
cortex [514,515]. Based on their cytologic appearance,
surface characteristics and functional properties,
these lymphocytes are considered to be non-neoplastic
[516,517].
The majority of thymomas are encapsulated and
benign while the malignant ones comprise a minority.
Among these minority, most of them are defined as
malignant by virtue of their locally invasive behavior
[510,512,518]. However, some thymomas are unequivocal¬
ly malignant on cytologic grounds. Tumors of these
types have been designated thymic carcinoma to
distinguish them from those malignant thymomas
without cytologic atypia [512]. Most of them are
squamous cell carcinoma [512,519,520,521], undifferen¬
tiated carcinomas [512,521], or lymphoepithelioma-like
carcinomas [512,521] (see appendix II).
In 1985, Leyvraz and associates [442] reported the
detection of EBV genome in lymphoepithelioma-like
carcinoma of the thymus. Similar finding was also seen
by Huang's group in a Chinese patient [522]. In the
EBV DNA positive thymic tumors tested in my experiment,
they belongs to malignant thymoma but not
lymphoepithelioma-like (one with MG and the other
without). These findings, thus extending the EBV-
associated malignant thymic tumor to include non-
lymphoepithelioma-like lesions.
In addition, EBV DNA was also detected in two
patients with thymic lymphoid (or follicular)
hyperplasia. They are characterized by comprising
germinal centers in the medulla and can be found in
patients with thyrotoxicosis [523], Addison's disease,
acromegaly, gonadal hypofunction, systemic lupus
erythematosus [524], scleroderma [525], rheumatoid
arthritis [526], and some liver diseases [527].
However, among all, myasthenia gravis (MG) shows the
strongest association, namely 75—84% of the patients
contain this thymic abnormality [512]. My finding of
EBV DNA in both tumorous (thymomas) and non-tumorous
(myasthenic thymic hyperplasia) lesions in the thymus
gland is analogous to that seen in the parotid gland,
where EBV DNA can be detected in the Sjogren syndrome
[499] as well as MLEL. Moreover, supplemented to
Leyvraz's group studies [442], I had also tried to
detect EBV DNA in the normal thymus but negative result
was obtained.
Summing up the findings in different thymus
tissues, EBV DNA could be detected in both myasthenic
hyperplasia and thymoma tissues. In the former cases,
it is possible that the EBV genome came from the B-
cells of the germinal centers as EBVC3d receptor has
been found in this cell type [489,490]. Although
rarely germinal centers can be found in thymoma
especially in the patients with MG[ 528], it is
unlikely that the EBV DNA came from them since they are
scanty. Moreover, we could not find EBV DNA in two
normal thymus tissues which should harbor scanty
follicular structure, too [529].
CONCLUSION
In my experiment, Epstein-Barr virus DNA could be
detected in the Chinese cancer patients with
undifferentiated nasopharyngeal carcinoma, undifferen¬
tiated carcinoma of the parotid gland (MLEL) and
thymoma. In these involved organs, their epithelial
cells are all derived from the primitive pharynx.
Undifferentiated carcinomas developed in these sites
show a similar histological picture, with abundant
lymphocytic infiltration among the tumor cells. Thus
It is possible that these tumors share a common
etiological agent in oncogenesis. Although no one can
tell what is it now, these tumors contain detectable
Epstein-Barr virus genome. Moreover, the EBV
association can also be found in patients with
Sjogren's syndrome [499] (which contains the so called
benign lymphoepithelial lesion in the parotid gland
[530,531,532,533,534]) and lymphoepithelioma-1ike
carcinoma of lung [535]. It seems that
lymphoepithelioma-1ike lesions always associate with
Epstein-Barr virus.
Nevertheless, Epstein-Barr virus in these lesions
XAciy either involved in the pathogenesis or just a
passenger. In the latter case, rhe virus enters
malignant cell lineages after they have begun to
proliferate. Although no one can tell the exact role
of EBV now, some findings may be unbeneficial to the
passenger notion:
1. In all carcinomas arising from the Waldeyer's ring
related structure, the nasopharynx, parotid gland,
and palatine tonsil [90,438,439], there is
detectable EBV DNA.
2. The patients with Sjogren syndrome can also develop
benign and malignant thymoma [518,536].
3. The benign lymphoepithelial lesion (BLEL), which is
a common manifestation of Sjogren's syndrome in the
parotid gland, has been suggested to giving rise the
malignant lymphoepithelial lesion (MLEL) [495,535,
537,538]. Thus Epstein-Barr virus seems to involve
a group of related diseases.
4. Epstein-Barr virus DNA has direct tandem repeats of
about 500 bp at each terminus. They are responsible
for circularization of the viral genome to form the
closed episomal DNA. The number of reiteration of
these repeats is heterogeneous among different
viruses. By using a franking fragment of the
terminal repeat (TR) as a probe, Southern blot
hybridization of the DNA isolated from EBV-
associated tumors can be carried out [539].
Detection of a single band can indicate the EBV
episomes in the tumor cells have a consistent copy
number of terminal repeat. This will imply the
progenitor cell of the tumor was infected with a
single form of EBV. It also implies the monoclonal
cellular proliferation occurred after EBV infection.
By using this approach, Raab-Traub and Flynn found
that both undifferentiated nasopharyngeal carcinoma
and parotid gland carcinoma are derived from a
single EBV-infected progenitor cell [200].
In order to prove the oncogenic role of EBV,
studies should be carried out based on the criteria
proposed by Henle for oncogenic virus [1]:
1. Virus, virus-determined antigens, or virus nucleic
acid must be present in all the tumor cells;
2. Antibodies to virus-determined antigens must occur
at higher frequency andor titres with given
malignancies than in controls;
3. The virus must be capable of transforming normal
cells in vitro; and
4. The virus must be capable of tumor induction in
subhuman primates.
Obviously, what I have done is just opening the
door of a long journey, more intensive works must be
done to clarify the answers.
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1. With no or minimal cytologic atypia
a. Locally invasive (usual form)
b. With true lymphatic or hematogenous spread
(rare)
2. Cytologically malignant(= thymic carcinoma)
morphologic variants
a. Squamous cell carcinoma
b. L y m p h o e pi t h e I i oma- I ike
c. Clear cell carcinoma
d. Sarcomatoid (electron microscopy often needed
to distinguish from epithelial tumours)
e. Undifferentiated (electron microscopy often
needed to distinguish from histiocytic
lymphoma and germ cell tumours)
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